

ΜΑΡΙΟΣ ΔΗΜΟΠΟΥΛΟΣ
ΦΥΣΙΚΟΠΑΘΗΤΙΚΟΣ



ΟΛΙΣΤΙΚΗ ΙΑΤΡΙΚΗ & ΚΑΡΚΙΝΟΣ

ΑΠΟ ΤΗΝ ΑΡΧΑΙΟΤΗΤΑ ΕΩΣ ΣΗΜΕΡΑ

ΒΙΒΛΙΟΓΡΑΦΙΚΕΣ ΑΝΑΦΟΡΕΣ

ΕΚΔΟΣΕΙΣ ETRA

Τίτλος: Ολιστική ιατρική και καρκίνος
Από την αρχαιότητα έως σήμερα

Συγγραφέας: Μάριος Δημόλουλος

ISBN: 978-960-6830-98-3

Επιμέλεια έκδοσης: Βάλλυ Καλοζούμη
Διορθώσεις: Βάλλυ Καλοζούμη
Εξώφυλλο: Γεράσιμος Ε. Κατραμάδος

2022 © Εκδόσεις ETRA
Ευεργετών 7, Π. Φάληρο, 17563
Τ: 210 9811753
www.etra.gr

Ο συγγραφέας αυτού του βιβλίου δεν παρέχει ιατρικές συμβουλές ούτε συνταγογραφεί τη χρήση οποιασδήποτε τεχνικής ως μορφή θεραπείας για σωματικά, συναισθηματικά ή ιατρικά προβλήματα χωρίς τη συμβουλή γιατρού, είτε άμεσα είτε έμμεσα. Η πρόθεση του συγγραφέα είναι μόνο να προσφέρει πληροφορίες γενικής φύσης για να σας βοηθήσει στην προσπάθειά σας για συναισθηματική, σωματική και πνευματική ευεξία. Σε περίπτωση που χρησιμοποιήσετε οποιαδήποτε από τις πληροφορίες αυτού του βιβλίου για τον εαυτό σας, ο συγγραφέας και ο εκδότης δεν αναλαμβάνουν καμία ευθύνη για τις ενέργειές σας.

Κανένα μέρος του παρόντος βιβλίου δεν επιτρέπεται να αναπαραχθεί με οποιαδήποτε μηχανική, φωτογραφική ή ηλεκτρονική διαδικασία ή με τη μορφή φωνογραφικής εγγραφής, ούτε να αποθηκευτεί σε σύστημα ανάκτησης, να μεταδοθεί ή να αντιγραφεί με οποιονδήποτε άλλο τρόπο για δημόσια ή ιδιωτική χρήση -εκτός από τη "θεμιτή χρήση" ως σύντομων αποσπασμάτων που ενσωματώνονται σε άρθρα και κριτικές- χωρίς προηγούμενη γραπτή άδεια του εκδότη.

ΜΕΡΟΣ Ι

1. Ευστάθιος 1494,II
2. Ιλιάδα, Ε900
3. Πλούταρχος, Συμποσιακά, Προβλήμ. Γ
4. Φερεκύδης και σχόλια Ευσταθίου στην Οδύσσεια του Ομήρου, λ, στ. 287-297
5. Τσουκαντάς Γ, Κουρέτας Δ, Η Ψυχοκαθαρτική μέθοδος θεραπείας της ατεκνίας του Ιφίκλου υπό του Μελάμποδος – Εφαρμογαί της Ψυχαναλύσεως εις την αρχαίαν μυθολογίαν. περ. Πλάτων
6. Γαληνός, 1ος τόμος εκδ. Κηη, τ.14, σελ.674
7. Απολλόδωρος, Β,2,3
8. Υγίνος, Μύθοι, CCLXXIV, 9
9. Ισίδωρος, Ετυμολογίαι, IV, 3, 1-2
10. Κικέρων, «Περί της των Θεών φύσεως», 111, 22, 67
11. Μυλωνάς Γ, Πολύχρυσοι Μυκήναι, 1983
12. Κούζης Α. Ιστορία της ιατρικής, 1930, σελ. 51,52
13. Ath. Mitth.1941, σελ.67
14. Παλατινή Ανθολογία, I 330
15. Inscriptiones Graecae IV, 1 αρ. 121-122
16. Ιατρικαί Συναγωγαί, ΧΚV,30,10-14
17. Αραβαντινός Α.Π. Ασκληπιός και Ασκληπιεία, σελ. 8
18. Πausanías, Α,340
19. Στράβων, ΙΔ, 650
20. Ανδρουτσόπουλος Σ. Το Ιεροθεραπευτήριον του Αμφιαράου στον Ωρωπό, σελ.12
21. Ιάμβλιχος, Περί του Πυθαγορικού Βίου XXXI, 208
22. Inscriptiones Graecae IV, 1 ar. 126
23. Ιάμβλιχος, Περί του Πυθαγορικού Βίου, XV
24. Πλάτων, Χαρμίδης, 156E
25. Ξενοφών, Απομν. Δ, 6, 10
26. Ιπποκράτης, Περί Ενυπνίων, παρ. 1
27. Ιπποκράτης, Περί χυμών, παρ.9
28. Ιπποκράτης, Περί εβδομάδων, εκδ. littre IX, κεφ 45, σελ. 460
29. Γαληνός. XVII, 219, I, 832
30. Γαληνός, I, 732 και XVI, 219
31. Αριστοτέλης, Περί της καθ' ύπνον μαντικής, 1463α 4
32. Πλούταρχος, Βίος Αντιφώντος, 18

33. Πausanías Θ, 39,8
34. Αργοναυτικά του Ορφέως, στ.51-52, 131-132, 378-400
35. Εγκυκλοπαιδικό λεξικό Ηλίου, τ. ΚΒ, σελ. 466
36. Ανδρουτσόπουλος Γ. Το Ιεροθεραπευτήριο του Αμφιαράου εν Ωρωπώ, σελ.20
37. Μαργιωρής Ν, Θεραπεία με εγχοίμηση. Ηθεραπευτική των προαιώνων μέσα στα Ασκληπιεία και τα Αμφιαράεια, σελ.17-21, 1987
38. Βίλχελμ Ράιχ, Ο Συσσωρευτής Οργόνης. Η ιατρική και επιστημονική του χρήση, εκδ. Χρ. Μουσουλιώτη, σελ.16
39. Κέλλσος, De Medicina, κεφ. 2-8
40. Πλούταρχος. Περί Αρεσκόντων φιλοσόφοις, β, 5, 609
41. Διογένης Λαέρτιος, β Ιχ, VIII
42. Αιλιανός, Ποικίλη Ιστορία, ΙΧ
43. Σακελαρίου Γ. Πυθαγόρας ο Διδάσκαλος των Αιώνων, 1963, σελ. 358
44. Ιάμβλιχος, Βίος Πυθαγόρα, ΚΔ, παρ.106
45. Ιάμβλιχος, Βίος Πυθαγόρου, κεφ. 15
46. Πλίνιος, Naturalis Historia XXV,2(5),13
47. Σακελαρίου Γ. Πυθαγόρας ο Διδάσκαλος των Αιώνων, 1963, σελ.360
48. Ιπποκράτης, Περί τόπων των κατά άνθρωπον» 42
49. Ιπποκράτης, Περί Φυσών, κεφ. 1
50. Ιπποκράτης, Αφορισμοί, ΙΙ, 22
51. Fr.854 Radt-πλουτάρχου, «Περί ησυχίας ψυχής», κεφ. 7, 468b
52. Βαρθολομαίος Τ. Η ιατρική ομοιοπαθητική στην Ελλάδα, περιοδικό Medicum – Εναλλακτική Θεραπευτική», τεύχος 1. Ιανουάριος 2001
53. Ιπποκράτης, Περί Αρχαίας Ιατρικής, 622.14
54. Ιπποκράτης, Περί Αρχαίας Ιατρικής, 578,3
55. Ιπποκράτης, Περί Διαίτης, Α, παρ.2
56. Ιπποκράτης, Περί Διαίτης, παρ. 33
57. Ιπποκράτης, Περί Διαίτης, παρ. 56
58. Ιπποκράτης, Περί Διαίτης Υγιεινής, παρ. 2
59. Ορειβάσιος ΙΙΙ, 168 εξ. Fr 141 Welmann
60. Ιπποκράτης, Περί Παθών, παρ. 40-44
61. Murray M, Pizzorno J, Encyclopedia of Natural Medicine, 2000, 464
62. Πλάτων, Πολιτεία» ΙΙΙ, 404e
63. Πλάτων, Πολιτεία, ΙV 426a-b
64. Πλάτων, Επιστολή 7η, 330d
65. Πλάτων, Τίμαιος, 88-89b-d
66. Ιπποκράτης, Παραγγελία, 14
67. Ιπποκράτης, Περί Διαίτης, παρ. 2

68. Εγκυκλοπαιδική επιθεώρηση 'Ηλιος, τεύχος 375, έτος 11ο, τόμος 20^{ος}
69. Ιπποκράτης, Περί Διαίτης, παρ. 2
70. Πλάτων, Χαρμίδης, IV, 156B
71. Πλάτων, Νόμοι» IX 857c-e
72. Πλάτων, Φαίδρος, 270c
73. Ιπποκράτης, Περί Διαίτης, I, XXV, 1-3
74. Ιπποκράτης, Περί Διαίτης, B, 61
75. Ιπποκράτης, Περί Διαίτης οξέων, XI
76. Ιπποκράτης, Περί χυμών, παρ. 9
77. Αριστοτέλης, Φυσιognωμικά, 805α-1
78. Αριστοτέλης, Φυσιognωμικά, 808 β-12
79. Αριστοτέλης, Προβλήματα, IA-53, H -20
80. Ιπποκράτης, Φυσιognωμικά, 808 β-23
81. Jensen B, Τροφές που θεραπεύουν, εκδ. Διόπτρα, σελ 33

ΜΕΡΟΣ II

1. Knaus H. Corporate profile, Ciba Geigy: pushing pills and pesticides. Multinational Monitor. 1993
2. Hansson O. Arzneimittel-Multis und der SMON-Skandal. Berlin: Arzneimittel-Information-Dienst CmbH, 1979.
3. Hench PS, Kendall EC, Slocumb CH, et al. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocortisone; Compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Mett Mayo Clin. 1949, 24:181-97.
4. Gotzsche P. Deadly Medicines and Organized Crime. How Big Pharma Has Corrupted Healthcare, 2013.
5. Pearce N. Adverse Reactions: the fenoterol story. Auckland: Auckland University Press, 2007.
6. Gotzsche P. Deadly Medicines and Organized Crime. How Big Pharma Has Corrupted Healthcare, 2013.
7. Andersen LA, Gotzsche PC. Naproxen and aspirin in acute musculoskeletal disorders: a double-blind, parallel study in sportsmen. Pharmatherapeutica, 1984, 3:535-41.
8. Gotzsche PC. Review of dose-response studies of NSAIDs in rheumatoid arthritis. Dan Med Bull. 1989, 36:395-9.
9. Abraham J. Science, Politics and the Pharmaceutical Industry, Lon-

- don: UCL Press, 1995.
10. Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. *BMJ*, 1996, 312:1563-6.
 11. Joyce C, Lesser F. Opren deaths kept secret, admits Lilly. *New Sci.* 1985, 107:15-6.
 12. Abraham J. *Science, Politics and the Pharmaceutical Industry*, London: UCL Press, 1995.
 13. Ark. judge fines Johnson & Johnson more than \$1.1B in Risperdal case. CBS/AP. April 11 2012 <https://www.cbsnews.com/news/ark-judge-fines-johnson-johnson-more-than-11b-in-risperdal-case/>
 14. Soreth J, Cox E, Kweder S, et al. Ketek – the FDA perspective. *N Engl J Med*, 2007, 356:1675-6.
 15. Gotzsche P. *Deadly Medicines and Organized Crime. How Big Pharma Has Corrupted Healthcare*,
 16. Zee A van. The promotion and marketing of Oxycontin: commercial triumph, public health tragedy. *Am J Publ Health*, 2009, 99:221-7.
 17. Wordsworth M. Deadly epidemic fears over common painkiller, ABC News, November 14 2012.
 18. Kendall B. Court backs crackdown on drug officials. *Wall Street Journal*, July 27 2010.
 19. Rossouw JE, Anderson CL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA*. 2002, 288:321-33.
 20. Salpeter SR, Buckley NS, Ormiston TM, et al. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. *Ann Intern Med*. 2006, 144:904-12.
 21. Caldwell B, Aldington S, Weatherall M, et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. *J R Soc Med*. 2006, 99:132-40.
 22. Sherman M, Marchione M. Pfizer: Celebrex raises heart attack risk. ABC News. December 17 2004. <https://www.abc.net.au/news/2004-12-18/arthritis-drug-linked-to-heart-attack-risk/604740>
 23. Harris G. Pfizer says internal studies show no Celebrex risks. *New York Times*. February 5 2005. <https://www.nytimes.com/2005/02/05/business/pfizer-says-internal-studies-show-no-celebrex-risks.html>
 24. Smith SM, Schroeder K, Fahey T. Over the counter (OTC) medica-

- tions for acute cough in children and adults in ambulatory settings. *Cochrane Database Syst Rev.* 2012, 8:CD001831.
25. Tomerac AAT, Vyas HHV, Lakhanpaul M, et al. Inhaled corticosteroids for treating non-specific chronic cough in children. *Cochrane Database Syst Rev.* 2005, 3:CD005373
 26. Sharfstein JM, North M, Serwint JR. Over the counter but no longer under the radar – pediatric cough and cold medications. *N Engl J Med.* 2007, 357:2321-4.
 27. Public Health Advisory: FDA Recommends that Over-the-Counter (OTC) Cough and Cold Products not be used for Infants and Children under 2 Years of Age. February 23 2011.
 28. The University Group Diabetes Program (UGDP): A Famous Early Randomized Clinical Trial (RCT) <http://www.epi.umn.edu/cvdepi/essay/the-university-group-diabetes-program-ugdp-a-famous-early-randomized-clinical-trial-rct/>
 29. The Endocrine Society. “Common diabetes drugs associated with increased risk of death.” *ScienceDaily.* ScienceDaily, 25 June 2012.
 30. Moore TJ. *Deadly Medicine: why tens of thousands of heart patients died in America’s worst drug disaster.* New York: Simon & Schuster, 1995.
 31. Wise J. European drug agency criticizes Roche for failing to report adverse reactions and patient deaths. *BMJ.* 2012, 344:e4344.
 32. European Medicines Agency acts on deficiencies in Roche medicines-safety reporting. <https://www.ema.europa.eu/en/news/european-medicines-agency-acts-deficiencies-roche-medicines-safety-reporting>
 33. RxList. Propulsid. <https://www.rxlist.com/propulsid-drug.htm#description>
 34. William D. How a new policy led to seven deadly drugs. *Los Angeles Times.* December 20, 2000.
 35. Wood J, Elsom J. Ten suicides this year are linked to powerful acne drug Roaccutane as medicines watchdog launches probe over safety fears. *DailyMail.* 27 December 2019. <https://www.dailymail.co.uk/news/article-7830129/Ten-suicides-year-linked-powerful-acne-drug-Roaccutane-figures-show.html>
 36. Anonymous. Suicides linked to acne drug Roaccutane as regulator reopens inquiry. *The Guardian.* <https://www.theguardian.com/society/2019/dec/27/suicides-linked-to-acne-drug-roaccutane-as-regulator-reopens-inquiry>

37. Alfter B, Teugels M, Bouma J. Media lift lid on secret reports on drug side-effects. Euobserver, 22 October 2008. <https://euobserver.com/foreign/26973>
38. Wikipedia Aminorex <https://en.wikipedia.org/wiki/Aminorex>
39. RxList, Pondimin. <https://www.rxlist.com/pondimin-drug.htm#indications>
40. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. *N Engl J Med.* 1997, 337:581-8.
41. Wikipedia, Sibutramine. <https://en.wikipedia.org/wiki/Sibutramine>
42. Wikipedia, Benfluorex. <https://en.wikipedia.org/wiki/Benfluorex>
43. FDA, Safety clinical trial shows possible increased risk of cancer with weight-loss medicine Belviq, Belviq XR (lorcaserin). <https://www.fda.gov/drugs/drug-safety-and-availability/safety-clinical-trial-shows-possible-increased-risk-cancer-weight-loss-medicine-belviq-belviq-xr>
44. Krumholz HM, Ross JS, Presler AH, et al. What have we learned from Vioxx? *BMJ.* 2007, 334:120-3.
45. Lenzer J. FDA is incapable of protecting US against another Vioxx, *BMJ.* 2004, 329:1253.
46. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. *N Engl J Med.* 2005, 352:1092-102.
47. Gotzsche P. *Deadly Medicines and Organized Crime. How Big Pharma Has Corrupted Healthcare*, 2013.
48. Ferrara M. Vioxx Killed Half a Million? The Facts Are Grim. *The Legal Examiner.* May 1, 2012. <https://affiliates.legalexaminer.com/health/vioxx-killed-half-a-million-the-facts-are-grim/>
49. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial of colorectal adenoma prevention. *N Engl J Med.* 2005, 352:1071-80.
50. Caldwell B, Aldington S, Weatherall M, et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. *J R Soc Med.* 2006, 99:132-40.
51. Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala N, Emberson J, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. *Lancet.* 2013;382(9894):769-779.

52. Blower AL, Brooks A, Fenn GC, et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. *Aliment Pharmacol Ther.* 1997, 11:283-91.
53. Cohen D. Rosiglitazone: what went wrong? *BMJ.* 2010, 341:530-534.
54. Harris G. Diabetes drug maker hid test data, files indicate. *New York Times.* July 13, 2010. <https://www.nytimes.com/2010/07/13/health/policy/13avandia.html>
55. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *N Engl J Med.* 2007, 356:2457-71.
56. Moynihan R. Rosiglitazone, marketing, and medical science. *BMJ.* 2010, 340: c1848.
57. Wikipedia, Triglitzazone. <https://en.wikipedia.org/wiki/Troglitazone>
58. Kendall DM, Rubin CJ, Mohideen P, Ledezine JM, Belder R, Gross J, et al.. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study. *Diabetes Care.* 2006, 29 (5): 1016–23.
59. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. *JAMA.* 2005, 294 (20): 2581–6.
60. Angell M. The illusions of psychiatry. *New York Rev Books.* August 18, 2011. <https://www.nybooks.com/articles/2011/07/14/illusions-of-psychiatry/>
61. Harris G, Carey B, Roberts J. Psychiatrists, children and drug industry's role. *New York Times.* May 10, 2007. <https://www.nytimes.com/2007/05/10/health/10psyche.html>
62. Martin A, Young C, Leckman JF, et al. Age effects on antidepressants-induced manic conversion. *Arch Pediatr Adolesc Med.* 2004, 158:773-80.
63. Coupland C, Dhiman P, Morriss R, et al. Antidepressants use and risk of adverse outcomes in older people: population based cohort study. *BMJ.* 2011, 343:d4551.
64. Moore TJ, Glenmullen J, Furberg CD. Prescription drugs associated with reports of violence towards others. *PLoSOne.* 2010, 5:e15337.
65. Healy D. Reply to D. Wilkinson – Loss of anxiety and increased aggression in a 15-year-old boy taking fluoxetine. *J Psychopharmacol.*

- 1999, 13:421.
66. Orriols L, Delorme B, Gadegbeku B, et al. Prescription medicines and the risk of road traffic crashes: a French registry-based study. *PLoSMed*. 2010, 7:e1000366.
 67. Montejó A, Llorca G, Izquierdo J, et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multi-center study of 1022 outpatients. Spanish Working Group for the study of psychotropic-related sexual dysfunction. *J Clin Psychiatry*. 2001, 62(Suppl. 3):10-21.
 68. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. *Am J Psychiatry*. 1990, 147:207-210.
 69. Lenzer J. FDA to review 'missing' drug company documents. *BMJ*. 2005, 330:7.
 70. Lenzer J. Drug secrets: what the FDA isn't telling. *Slate*. September 27, 2005. <https://slate.com/technology/2005/09/what-the-fda-isn-t-telling.html>
 71. Gotzsche P. *Deadly Medicines and Organized Crime. How Big Pharma Has Corrupted Healthcare*, 2013.
 72. Fava GA, Bernardi M, Tomba E, et al. Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. *Int J Neuropsychopharmacol*. 2007, 10:835-8.
 73. de Gage SB, Begaud B, Bazin F, et al. Benzodiazepine use and risk of dementia: prospective population based study. *BMJ*. 2012, 345:e6231.
 74. Wang YC, Tai PA, Poly TN, et al. Increased Risk of Dementia in Patients with Antidepressants: A Meta-Analysis of Observational Studies. *Behav Neurol*. 2018;2018:5315098.
 75. Healy D. *Pharmageddon*. Berkeley: University of California Press, 2012.
 76. Berenson A. Eli Lilly said to play down risk of top pill. *New York Times*. December 17, 2006. <https://www.nytimes.com/2006/12/17/business/17drug.html>
 77. Schneider LS, Darerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. *JAMA*. 2005, 294:1934-43.
 78. Glaxo 'downplayed' warning on heart-attack risks from AIDS drug. *The Independent*. May 12, 2008. <https://www.independent.co.uk/news/science/glaxo-downplayed-warning-heart-attack-risk-aids->

- drug-826255.html
79. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. *JAMA*. 1996 Jan 3;275(1):55-60.
 80. Iwata H, Matsuo K, Hara S, et al. Use of hydroxy-methyl-glutaryl co-enzyme A reductase inhibitors is associated with risk of lymphoid malignancies. *Cancer Sci*. 2006 Feb;97(2):133-8.
 81. Chang CC, Ho SC, Chiu HF, Yang CY. Statins increase the risk of prostate cancer: a population-based case-control study. *Prostate*. 2011 Dec;71(16):1818-24.
 82. Azoulay L, Yin H, Filion KB, Assayag J, Majdan A, Pollak MN, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. *BMJ* 2012;344:e3645.
 83. Hillaire-Buys D, Faillie JL. Pioglitazone and the risk of bladder cancer. *BMJ*. 2012, 344:e3500.
 84. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. *Gastroenterology*. 2011, 141:150-6.
 85. Maxmen A. Debate on diabetes drugs gathers pace: petition unveils unnerving reports on potential carcinogenicity of GLP-1 mimics. *Nature*. April 30, 2012.
 86. Wikipedia, Liraglutide. <https://en.wikipedia.org/wiki/Liraglutide>
 87. FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022341lbl.pdf
 88. Kragh A. Two out of three persons living in nursing homes for the elderly are treated with at least ten different drugs. A survey of drug prescriptions in the northeastern part of Skane. *Lakartidningen*. 2004, 101:994-9.
 89. Johnell K, Fastbom J. Multi-dose drug dispensing and inappropriate drug use: A nationwide register-based study of over 700,000 elderly. *Scand J Prim Health Care*. 2008;26(2):86-91.
 90. Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. *Arch Intern Med*. 2010, 170:1648-54.
 91. Ελεύθερο Βήμα, Ο Καθηγητής Γκρότε και η νεωτέρα «Θεραπευτική», 7/4/38.
 92. Κούζα Α. Η θεραπεία με χυλό σίτου, 1955.
 93. Περιοδικό Υγεία για Όλους, Δερματικές ασθένειες σε παιδιά και σε μεγάλους, τ. Β, σελ. 46-47.
 94. Licinio J., Wong M.L, The role of inflammatory mediators in the bi-

- ology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection, *Molecular Psychiatry*, 4, 317-327, 1999
95. Deon D., et al., Cross-talk between IL-1 and IL-6 signaling pathways in rheumatoid arthritis synovial fibroblasts, *J Immunol*, 167(9):5395-403, 2001
 96. Kanda T., et al., Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy, *J Diabetes Complications*, 15(5):257-9, 2001
 97. Feldmann M., et al., Role of cytokines in rheumatoid arthritis, 14:397-440, 1996
 98. Fernandes J.C., et al., The role of cytokines in osteoarthritis pathophysiology, *Biorheology*, 39(1-2):237-46, 2002
 99. Futani H., et al., Relation between interleukin-18 and PGE2 in synovial fluid of osteoarthritis: a potential therapeutic target of cartilage degradation, 25 Suppl 1:S61-4, 2002
 100. Nishimura M, et al., Proinflammatory cytokines and arthroscopic findings of patients with internal derangement and osteoarthritis of the temporomandibular joint, *British Journal of Oral and Maxillofacial Surgery*, 40, 1, 68-71, 2002
 101. Khalfoun B., et al, Docosahexanoic and eicosapentanoic acids inhibit in vitro human endothelial cell production of interleukin-6, *Adv Exp Med Biol*, 400B:589-97, 1997
 102. Cleland L.G., James M.J., Fish oil and rheumatoid arthritis: anti-inflammatory and collateral health benefits, *J Rheumatol*, 27(10):2305-7, 2000
 103. Kipper – Galperin M., Dehydroepiandrosterone selectively inhibits production of tumor necrosis factor alpha and interleukin-6 (correction of interleukin-6) in astrocytes, *Int J Dev Neurosci*, 17(8):765-75, 1999
 104. Reddi K., et al., Interleukin 6 production by lipopolysaccharide-stimulated human fibroblasts is potently inhibited by naphthoquinone (vitamin K) compounds, *Cytokine*, 7(3):287-290, 1995
 105. Shea M.K., et al., Vitamin K and vitamin D status: Associations with inflammatory markers in the Framingham offspring study, *Am J Epidemiol*, 167(3):313-320, 2008
 106. Neogi T., et al., Low vitamin K status is associated with osteoarthritis in the hand and knee, *Arthritis Rheum*, 54:1255-1261, 2006

107. Misra D., Vitamin K deficiency is associated with incident knee osteoarthritis, *Am J Med.*, 126(3):243-248, 2013
108. Purasiri P., et al., Modulation of cytokine production in vivo by dietary essential fatty acids in patients with colorectal cancer, *Clin Sci (Lond)*, 87(6):711-7, 1994
109. Dirks J., Cytokine levels affected by gamma-linolenic acid, *Prostaglandins Leukot Essent Fatty Acids*, 59(4):273-7, 1998
110. DeLuca P., et al., Effects of gamma linolenic acid on interleukin-1 beta and tumor necrosis factor-alpha secretion by stimulated human peripheral blood monocytes: studies in vitro and in vivo, *J Invest Med*, 47:246-50, 1999
111. Teucher T., et al., Cytokine secretion in whole blood of healthy subjects following oral administration of *Urtica dioica* L. plant extract, *Arzneimittelforschung*, 46(9):906-10, 1996
112. Gosset P., et al., Thiol regulation of the production of TNF-alpha, IL-6 and IL-8 by human alveolar macrophages, *Eur Respir J*, 14(1):98-105, 1999
113. Devaraj S., et al., The effects of alpha tocopherol supplementation on monocyte function: decreased lipid oxidation, interleukin 1 β secretion and monocyte adhesion to endothelium, *Journal of Clinical Investigation*, 98(3):756-763, 2000
114. Demacker P.N., et al., α -tocopherol supplementation decreases production of superoxide and cytokines by leukocytes ex vivo in both normlipidemic and hyperglyceridemic individuals, *Am J Clin Nutr*, 71, 2, 458-464, 2000
115. Winrow V.R., et al., Free radicals in inflammation: Second messengers and mediators of tissue destruction, *Br Med Bull*, 49, 506, 1993
116. O'Byrne K.J., Dalglish A.G., Chronic immune activation and inflammation as the cause of malignancy, *British Journal of Cancer*, 85(4):473-483, 2001
117. Hietanen E., et al., Diet and oxidative stress in breast, colon, and prostate cancer patients: a case-control study, *European Journal of Clinical Nutrition*, 48(8):575-586, 1994
118. Hristozov D., et al., Evaluation of oxidative stress in patients with cancer, *Archives of Physiology and Biochemistry*, 109(4):331-336, 2001
119. Yamamoto Y., et al, Advanced glycation endproducts-receptor interactions stimulate the growth of human pancreatic cancer cells through the induction of platelet-derived growth factor-B, *Biochem-*

- ical and Biophysical Research Communications, 22(3):700-705, 1996
120. Hiroki H., et al., Expression of receptors for advanced glycation end-products (rage) is closely associated with the invasive and metastatic activity of gastric cancer, *Journal of Pathology*, 192(2):163-170, 2002
 121. McWhorter W.P., Allergy and risk of cancer: A prospective study using NHANESI (First National Health and Nutrition Examination Survey) followup data, *Cancer*, 62:451, 1988
 122. Shils M.E., Goodhart R.S., *Nutrition and Neoplasia, Modern Nutrition in Health and Disease*, 1980
 123. Coleman V. *How To Stop Your Doctor Killing You*. 2019.
 124. Λαγγουράνης Α. *Ποιος μπορεί να μας γιατρέψει*. Εκδ. Κουκκίδα, 2008.
 125. Shoenfeld Y, Agmon-Levin N, Tomljenovic L. *Vaccines and Autoimmunity*. Wiley-Blackwell; 1st edition. 2015.
 126. Δημόπουλος Μ. Εμβόλια, αλουμίνιο και αυτισμός: Συνέντευξη του Dr. Chris Shaw στον Μάριο Δημόπουλο. 23 Οκτωβρίου 2017. <https://mariosdimopoulos.com/featured/emvolia-alouminio-kai-aftismos-sinentefksi-tou-dr-chris-shaw-ston-mario-dimopoulo/>
 127. Diamond H, Diamond M. *Fit for Life*. 1989.
 128. Willcox BJ, Willcox DC, Suzuki M. *The Okinawa Program: How the World's Longest-Lived People Achieve Everlasting Health--And How You Can Too*. 2002.

ΜΕΡΟΣ ΙΙΙ

1. Ιπποκράτης, Αφορισμοί, 6,38
2. Ιπποκράτης, Επιδημιαί, βιβλίο Ε, παρ. 101
3. Αποστολίδης ΠΔ, Η Μυθιστορία του καρκίνου στον Ιπποκράτη, εκδ. Στιγμή, σελ 16, 2002
4. Αέτιος, *Iatricorum libri*, XVI
5. Γαληνός, Χ978, 979
6. Ιπποκράτης, Αφορισμοί, 6.38
7. Ηρόδοτος, Ιστορία Γ' Θάλεια, 133-134
8. Ηρόδοτος, Ιστορία Γ', Θάλεια, 131-132
9. Γαληνός, Χ 976, 979

10. Ανασής Ε, Ο καρκίνος και τα φαρμακευτικά βότανα της χώρας, σελ. 11, 1976
11. Αποστολίδης Π, Η μυθιστορία του καρκίνου στον Ιπποκράτη, εκδ. Στιγμή, σελ. 23, 2002
12. Γαληνός In Hippokratis aphorismos commentary» VII
13. Καθημερινή, Ο υγιεινός δεκάλογος του Ιπποκράτη, 17 Σεπτεμβρίου 2000
14. Ιπποκράτης, Περί Φύσιος Ανθρώπου, παρ. 2
15. Ιπποκράτης, Περί Αέρων, Υδάτων, Τόπων, κεφ. 10
16. Gaston Durville, Η φύση θεραπεύει, σελ. 91-93, εκδ. Βασδέκης, 1993
17. Γαληνός, Χ 976, 979
18. Πλάτων, Χαρμίδης, IV, 156B

ΜΕΡΟΣ IV

1. Walters R., Options: The Alternative Cancer Therapy Book, 1993
2. Moss R., The Cancer Industry, 1996
3. Jang, D. H., Hoffman, R. S. Heavy metal chelation in neurotoxic exposures. *Neurol Clin.* 2011;29(3):607–22
4. Sinicropi, M. S., Amantea, D., Caruso, A., Saturnino, C. Chemical and biological properties of toxic metals and use of chelating agents for the pharmacological treatment of metal poisoning. *Arch Toxicol.* 2010;84(7):501–20
5. Galanis, A., Karapetsas, A., and Sandaltzopoulos, R. Metal-induced carcinogenesis, oxidative stress and hypoxia signalling. *Mutat Res.* 2009;674(1-2):31–5
6. Koedrith, P., and Seo, Y. R. Advances in carcinogenic metal toxicity and potential molecular markers. *Int J Mol Sci.* 2011;12(12):9576–95
7. Arita A, Costa M. Epigenetics in metal carcinogenesis: nickel, arsenic, chromium and cadmium. *Metallomics : integrated biometal science.* 2009;1(3):222-228.
8. Martinez-Zamudio R, Ha HC. Environmental epigenetics in metal exposure. *Epigenetics: official journal of the DNA Methylation Society.* Jul 2011;6(7):820-827.
9. Sinicropi, M. S., Amantea, D., Caruso, A., Saturnino, C. Chemical and biological properties of toxic metals and use of chelating agents for the pharmacological treatment of metal poisoning. *Arch Toxicol.*

- 2010;84(7):501–20
10. Knave B., Electric magnetic fields and health outcomes – An overview, *Scandinavian Journal of Work, Environment and Health*, 1994
 11. Ezzell C., Power – Line static: Debater rage over the possible hazards of electromagnetic fields, *Science News* 140, September 1991
 12. Moskowitz JM. We Have No Reason to Believe 5G Is Safe. *Scientific American*. October 17, 2019. <https://blogs.scientificamerican.com/observations/we-have-no-reason-to-believe-5g-is-safe/>
 13. https://www.iarc.fr/wp-content/uploads/2018/07/pr208_E.pdf
 14. https://www.niehs.nih.gov/ntp-temp/tr595_508.pdf
 15. Carlberg M, Hardell L. Evaluation of Mobile Phone and Cordless Phone Use and Glioma Risk Using the Bradford Hill Viewpoints from 1965 on Association or Causation. *Biomed Res Int*. 2017;2017:9218486.
 16. Κατραμάδος Γ. [Έρευνα]: Η τεχνολογία 5G, οι παρενέργειες και η επιστημονική τους τεκμηρίωση. *Holistic Life*. Τεύχος 98. 21 Ιουλίου 2020.
 17. Κάπνισμα και ραδιενέργεια, περ. Υγεία για Όλους, τ. 4-5, σελ. 60
 18. Chen CC, David AS, Nunnerley H, et al. Adverse life events and breast cancer: case-control study. *BMJ*. 1995 Dec 9;311(7019):1527-30.

ΜΕΡΟΣ V

1. Bahler DW, Levy R. Clonal evolution of a follicular lymphoma: evidence for antigen selection. *Proc Natl Acad Sci U S A*. 1992 Aug 1;89(15):6770-4.
2. Ishikawa F. Telomere crisis, the driving force in cancer cell evolution, *Biochem Biophys Res Commun*. 1997;230(1):1-6.
3. Pasqualini JR, Chetrite G, Nguyen BL, et al. Estrone sulfate-sulfatase and 17 beta-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence. *J Steroid Biochem Mol Biol*. 1995 Jun;53(1-6):407-12.
4. Monteiro HP, Stern A. Redox modulation of tyrosine phosphorylation-dependent signal transduction pathways. *Free Radic Biol Med*. 1996;21(3):323-33.

5. Dröge W. Free radicals in the physiological control of cell function. *Physiol Rev.* 2002 Jan;82(1):47-95.
6. Yamamoto Y, Yamashita S. Plasma ratio of ubiquinol and ubiquinone as a marker of oxidative stress. *Mol Aspects Med.* 1997;18 Suppl:S79-84.
7. Oberley TD, Oberley LW. Antioxidant enzyme levels in cancer. *Histol Histopathol.* 1997 Apr;12(2):525-35.
8. Gray MW, Burger G, Lang BF. The origin and early evolution of mitochondria. *Genome Biol.* 2001;2(6):REVIEWS1018.
9. Beckman KB, Ames BN. Mitochondrial aging: open questions. *Ann N Y Acad Sci.* 1998 Nov 20;854:118-27.
10. Daban JR. Physical constraints in the condensation of eukaryotic chromosomes. Local concentration of DNA versus linear packing ratio in higher order chromatin structures. *Biochemistry.* 2000 Apr 11;39(14):3861-6.
11. Woodcock CL, Dimitrov S. Higher-order structure of chromatin and chromosomes. *Curr Opin Genet Dev.* 2001 Apr;11(2):130-5.
12. Mitchel M. *An Introduction to Genetic Algorithms (Complex Adaptive Systems)*, The MIT Press;Reprint edition, 1998.
13. Goldberg DE, *Genetic Algorithms in Search, Optimization, and Machine Learning*, Addison-Wesley, Boston. USA. 1989.
14. Boland CR, Ricciardiello L. How many mutations does it take to make a tumor? *Proc Natl Acad Sci U S A.* 1999 Dec 21;96(26):14675-7.
15. Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from *Enterococcus faecalis* NCTC 12201 to *Staphylococcus aureus*. *FEMS Microbiol Lett.* 1992 Jun 1;72(2):195-8.
16. Davies J. Inactivation of antibiotics and the dissemination of resistance genes. *Science.* 1994 Apr 15;264(5157):375-82.
17. Kruse H, Sorum H. Transfer of multiple drug resistance plasmids between bacteria of diverse origins in natural microenvironments. *Appl Environ Microbiol.* 1994 Nov;60(11):4015-21.
18. Ainsworth C. Life's greatest inventions: multicellularity. *New Scientist.* 2005, 27.
19. Hamilton WD. Geometry for the selfish herd. *J Theor Biol.* 1971 May;31(2):295-311.
20. Marzluff J. Communal roosts of common ravens are mobile information centers. *Animal Behavior.* 1996;51:89-103.
21. Heinrich B. *Winter world: the ingenuity of animal survival*, Ecco, New York. 2004.

22. Soltis DE, Advances in the study of polyploidy since plant speciation. *New Phytologist*. 2004;161(1):173-191.
23. Yosida TH. Karyotype evolution and tumor development. *Cancer Genet Cytogenet*. 1983 Feb;8(2):153-79.
24. O'Brien SJ, Menotti-Raymond M, Murphy WJ, et al. The promise of comparative genomics in mammals. *Science*. 1999 Oct 15;286(5439):458-62, 479-81.
25. Digby L. The etiology of *Primula kewensis* and of the other related *Primula* hybrids. *Ann Bot*. 1912;26:357-388.
26. Grant V. *Plant Speciation*. Columbia Press, New York. 1981.
27. Ramsey J, Schemske DW. Pathways, mechanisms, and rates of polyploid formation in flowering plants. *Annual Review of Ecology and Systematics*. 1998;29:467-561.
28. Mayr F. *What Evolution Is*, Basic Books, Philadelphia, USA, 2002.
29. Oshimura M, Barrett JC. Chemically induced aneuploidy in mammalian cells: mechanisms and biological significance in cancer. *Environ Mutagen*. 1986;8(1):129-59.
30. Carmody RJ, Cotter TG. Signalling apoptosis: a radical approach. *Redox Rep*. 2001;6(2):77-90.
31. Frade JM, Michaelidis TM. Origin of eukaryotic programmed cell death: a consequence of aerobic metabolism? *Bioessays*. 1997 Sep;19(9):827-32.
32. Blackstone NW, Green DR. The evolution of a mechanism of cell suicide. *Bioessays*. 1999 Jan;21(1):84-8.
33. Green DR, Amarante-Mendes GP. The point of no return: mitochondria, caspases, and the commitment to cell death. *Results Probl Cell Differ*. 1998;24:45-61.
34. Ghibelli L, Coppola S, Fanelli C, et al. Glutathione depletion causes cytochrome c release even in the absence of cell commitment to apoptosis. *FASEB J*. 1999 Nov;13(14):2031-6.
35. Coppola S, Ghibelli L. GSH extrusion and the mitochondrial pathway of apoptotic signalling. *Biochem Soc Trans*. 2000 Feb;28(2):56-61.
36. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. *Cell*. 1997 Nov 14;91(4):479-89.
37. Krajewski S, Krajewska M, Ellerby JM, et al. Release of caspase-9 from mitochondria during neuronal apoptosis and cerebral ischemia. *Proc Natl Acad Sci USA*. 1999;96:5752-5757.
38. Shimizu S, Eguchi Y, Kamiike W, et al. Bcl-2 blocks loss of mitochon-

- drial membrane potential while ICE inhibitors act at a different step during inhibition of death induced by respiratory chain inhibitors. *Oncogene*. 1996 Jul 4;13(1):21-9.
39. Proskuryakov SY, Gabai VL, Konoplyannikov AG. Necrosis is an active and controlled form of programmed cell death. *Biochemistry (Mosc)*. 2002 Apr;67(4):387-408.
 40. Gilloteaux J, Jamison JM, Arnold D, et al. Cancer cell necrosis by autophagy: synergism of antitumor activity of vitamin C: vitamin K3 on human bladder carcinoma T24 cells. *Scanning*. 1998 Nov;20(8):564-75.
 41. Madeo F, Frohlich E, Frohlich KU. A yeast mutant showing diagnostic markers of early and late apoptosis. *J Cell Biol*. 1997 Nov 3;139(3):729-34.
 42. Ameisen JC. The origin of programmed cell death. *Science*. 1996 May 31;272(5266):1278-9.
 43. Lorenzo HK, Susin SA, Penninger J, Kroemer G. Apoptosis inducing factor (AIF): a phylogenetically old, caspase-independent effector of cell death. *Cell Death Differ*. 1999 Jun;6(6):516-24.
 44. Lennon SV, Martin SJ, Cotter TG. Dose-dependent induction of apoptosis in human tumour cell lines by widely diverging stimuli. *Cell Prolif*. 1991 Mar;24(2):203-14.
 45. Albina JE, Cui S, Mateo RB, Reichner JS. Nitric oxide-mediated apoptosis in murine peritoneal macrophages. *J Immunol*. 1993 Jun 1;150(11):5080-5.
 46. Dypbukt JM, Ankarcona M, Burkitt M, et al. Different prooxidant levels stimulate growth, trigger apoptosis, or produce necrosis of insulin-secreting RINm5F cells. The role of intracellular polyamines. *J Biol Chem*. 1994 Dec 2;269(48):30553-60.
 47. Escargueil-Blanc I, Meilhac O, Pieraggi MT, et al. Oxidized LDLs induce massive apoptosis of cultured human endothelial cells through a calcium-dependent pathway. Prevention by aurointricarboxylic acid. *Arterioscler Thromb Vasc Biol*. 1997 Feb;17(2):331-9.
 48. Sandstrom PA, Mannie MD, Buttke TM. Inhibition of activation-induced death in T cell hybridomas by thiol antioxidants: oxidative stress as a mediator of apoptosis. *J Leukoc Biol*. 1994 Feb;55(2):221-6.
 49. Sato N, Iwata S, Nakamura K, et al. Thiol-mediated redox regulation of apoptosis. Possible roles of cellular thiols other than glutathione in T cell apoptosis. *J Immunol*. 1995 Apr 1;154(7):3194-203.
 50. McGowan AJ, Bowie AG, O'Neill LA, Cotter TG. The production of a

- reactive oxygen intermediate during the induction of apoptosis by cytotoxic insult. *Exp Cell Res.* 1998 Jan 10;238(1):248-56.
51. McGowan AJ, Reactive oxygen intermediate(s) (ROI): common mediator(s) of poly(ADP-ribose)polymerase (PARP) cleavage and apoptosis, *FEBS Lett*, 1996;392:299-303.
 52. Greenlund LJ, Deckwerth TL, Johnson EM Jr. Superoxide dismutase delays neuronal apoptosis: a role for reactive oxygen species in programmed neuronal death. *Neuron.* 1995 Feb;14(2):303-15.
 53. Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. *Cell.* 1993 Oct 22;75(2):241-51.
 54. Slater AF, Nobel CS, Orrenius S. The role of intracellular oxidants in apoptosis. *Biochim Biophys Acta.* 1995 May 24;1271(1):59-62.
 55. Esposti MD, Hatzinisiriou I, McLennan H, Ralph S. Bcl-2 and mitochondrial oxygen radicals. New approaches with reactive oxygen species-sensitive probes. *J Biol Chem.* 1999 Oct 15;274(42):29831-7.
 56. Slater AF, Stefan C, Nobel I, van den Dobbelen DJ, Orrenius S. Signalling mechanisms and oxidative stress in apoptosis. *Toxicol Lett.* 1995 Dec;82-83:149-53.
 57. Greenhalf W, Stephan C, Chaudhuri B. Role of mitochondria and C-terminal membrane anchor of Bcl-2 in Bax induced growth arrest and mortality in *Saccharomyces cerevisiae*. *FEBS Lett.* 1996 Feb 12;380(1-2):169-75.
 58. Madeo F, Frohlich E, Ligr M, et al. Oxygen stress: a regulator of apoptosis in yeast. *J Cell Biol.* 1999 May 17;145(4):757-67.
 59. Xiang J, Chao DT, Korsmeyer SJ. BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases. *Proc Natl Acad Sci U S A.* 1996 Dec 10;93(25):14559-63.
 60. Carmody RJ, Cotter TG. Oxidative stress induces caspase-independent retinal apoptosis in vitro. *Cell Death Differ.* 2000 Mar;7(3):282-91.
 61. Creagh EM, Carmody RJ, Cotter TG. Heat shock protein 70 inhibits caspase-dependent and -independent apoptosis in Jurkat T cells. *Exp Cell Res.* 2000 May 25;257(1):58-66.
 62. Lesage S, Steff AM, Philippoussis F, et al. CD4+ CD8+ thymocytes are preferentially induced to die following CD45 cross-linking, through a novel apoptotic pathway. *J Immunol.* 1997 Nov 15;159(10):4762-71.
 63. Okuno S, Shimizu S, Ito T, et al. Bcl-2 prevents caspase-independent cell death. *J Biol Chem.* 1998 Dec 18;273(51):34272-7.

64. Aw TY, Ookhtens M, Kaplowitz N. Inhibition of glutathione efflux from isolated rat hepatocytes by methionine. *J Biol Chem*. 1984 Aug 10;259(15):9355-8.
65. Ghibelli L, Coppola S, Rotilio G, et al. Non-oxidative loss of glutathione in apoptosis via GSH extrusion. *Biochem Biophys Res Commun*. 1995 Nov 2;216(1):313-20.
66. van den Dobbelen DJ, Nobel CS, Schlegel J, et al. Rapid and specific efflux of reduced glutathione during apoptosis induced by anti-Fas/APO-1 antibody. *J Biol Chem*. 1996 Jun 28;271(26):15420-7.
67. Beaver JP, Waring P. A decrease in intracellular glutathione concentration precedes the onset of apoptosis in murine thymocytes. *Eur J Cell Biol*. 1995 Sep;68(1):47-54.
68. Ghibelli L, Fanelli C, Rotilio G, et al. Rescue of cells from apoptosis by inhibition of active GSH extrusion. *FASEB J*. 1998 Apr;12(6):479-86.
69. Fernandes RS, Cotter TG. Apoptosis or necrosis: intracellular levels of glutathione influence mode of cell death. *Biochem Pharmacol*. 1994 Aug 17;48(4):675-81.
70. Ameisen JC, Estaquier J, Idziorek T, De Bels F. Programmed cell death and AIDS pathogenesis: significance and potential mechanisms. *Curr Top Microbiol Immunol*. 1995;200:195-211.
71. Sian J, Dexter DT, Lees AJ, et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. *Ann Neurol*. 1994 Sep;36(3):348-55.
72. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. *Neurology*. 1996 Dec;47(6 Suppl 3):S161-70.
73. Wullner U, Loschmann PA, Schulz JB, et al. Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurons. *Neuroreport*. 1996 Mar 22;7(4):921-3.
74. King RJB. *Cancer Biology*, Pearson Education, Prentice Hall, Essex, England, 2000.
75. Gatenby RA. Models of tumor-host interaction as competing populations: implications for tumor biology and treatment. *J Theor Biol*. 1995 Oct 21;176(4):447-55.
76. Heim S, Mandahl N, Mitelman F. Genetic convergence and divergence in tumor progression. *Cancer Res*. 1988 Nov 1;48(21):5911-6.
77. Nowell PC. The clonal evolution of tumor cell populations. *Science*. 1976 Oct 1;194(4260):23-8.
78. Shapiro JR, Yung WK, Shapiro WR. Isolation, karyotype, and clonal growth of heterogeneous subpopulations of human malignant gli-

- omas. *Cancer Res.* 1981 Jun;41(6):2349-59.
79. Heppner GH, Miller FR. The cellular basis of tumor progression. *Int Rev Cytol.* 1998;177:1-56.
80. Preston-Martin S, Pike MC, Ross RK, et al. Increased cell division as a cause of human cancer. *Cancer Res.* 1990 Dec 1;50(23):7415-21.
81. Beisson J, Sonneborn TM. Cytoplasmic inheritance of the organization of the cell cortex in *Paramecium Aurelia*. *Proc Natl Acad Sci USA,* 1965 Feb;53(2):275-82.
82. Jablonka E, Lamb MJ. *Epigenetic Inheritance and Evolution.* Oxford University Press. 1995.
83. Mates JM, Sanchez-Jimenez FM. Role of reactive oxygen species in apoptosis implications for cancer therapy. *Int J Biochem Cell Biol,* 2000, 32(2), 157-170.
84. Cerutti PA, Prooxidant states and tumor promotion. *Science.* 1985, 227(4685), 375-381.
85. Conour JE, Graham WV, Gaskins HR. A combined in vitro/bioinformatic investigation of redox regulatory mechanisms governing cell cycle progression. *Physiol Genomics.* 2004, 18(2), 196-205.
86. McEligot AJ, Yang S, Meyskens Jr FI. Redox regulation by intrinsic species and extrinsic nutrients in normal and cancer cells. *Annu Rev Nutr.* 2005, 25, 261-295.
87. Smith J, Ladi E, Mayer-Proschel M, Noble M. Redox state is a central modulator of the balance between self-renewal and differentiation in a dividing glial precursor cell. *Proc Natl Acad Sci U S A.* 2000, 97(18), 10032-1007.
88. Bac YS, Kang SW, Sco MS, et al. Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. *J Biol Chem.* 1997. 272(1), 217-221.
89. Sundaresan M, Yu Z, Ferrans VJ, et al. Requirement for generation of HO for platelet-derived growth factor signal transduction. *Science.* 1995, 270(5234), 296-299.
90. Lo YY, Cruz TF. Involvement of reactive oxygen species in cytokine and growth factor induction of c-fos expression in chondrocytes. *J Biol Chem.* 1995, 270(20), 11727-11730.
91. Pani G, Colavitti R, Borello S, Galeotti T. Endogenous oxygen radicals modulate protein tyrosine phosphorylation and JNK-1 activation in lectin-stimulated thymocytes. *Biochem J.* 2000, 347(1), 173-181.
92. Hecht D, Zick Y. Selective inhibition of protein tyrosine phosphatase activities by H₂O₂ and vanadate in vitro. *Biochem Biophys Res Com-*

- mun. 1992, 188(2), 773-779.
93. Fialkow L, Chan CK, Downey GP. Inhibition of CD45 during neutrophil activation. *The Journal of Immunology*. 1997, 158(11), 5409-5417.
 94. Lee S, Yang K, Kwon J, et al. Reversible inactivation of the tumor suppressor PTEN by H₂O₂. *J Biol Chem*. 2002, 277(23), 20336-20342.
 95. Irani K, Xia Y, Zweier JL, et al. Mitogenic signaling mediated by oxidants in ras-transformed fibroblasts. *Science*. 1997, 275(5306), 1649-1652.
 96. Oberley TD. Oxidative damage and cancer. *American Journal of Pathology*. 2002, 160, 403-408.
 97. Maeda H, Akaike T. Nitric oxide and oxygen radicals in infection, inflammation, and cancer. *Biochemistry (Mosc)*. 1998, 63(7), 854-865.
 98. Burdon RH. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. *Free Radic Biol Med*. 1995, 18(4), 775-794.
 99. Mates JM, Sanchez-Jimenez FM. Role of reactive oxygen species in apoptosis implications for cancer therapy. *Int J Biochem Cell Biol*, 2000, 32(2), 157-170.
 100. Pani G, Colavitti R, Bedogni B, et al. A redox signaling mechanism for density-dependent inhibition of cell growth. *J Biol Chem*. 2000, 275(49), 38891-38899.
 101. Oberley TD. Oxidative damage and cancer. *American Journal of Pathology*. 2002, 160, 403-408.
 102. Oberley TD, Oberley LW. Antioxidant enzyme levels in cancer. *Histol Histopathol*, 1997, 12(2), 525-535.
 103. Coursin DB, Cihla HP, Sempf J, et al. An immunohistochemical analysis of antioxidant and glutathione S-transferase enzyme levels in normal and neoplastic human lung. *Histol Histopathol*. 1996, 11(4), 851-860.
 104. Oberley TD, Sempf JM, Oberley MJ, et al. Immunogold analysis of antioxidant enzymes in human renal cell carcinoma. *Virchows Arch*. 1994, 424(2), 155-164.
 105. Oberley TD, Sempf JM, Oberley LW. Immunogold analysis of antioxidant enzymes in common renal cancers. *Histol Histopathol*. 1996, 11(1), 153-160.
 106. Xu Y, Krishnan A, Wan XS, et al. Mutations in the promoter reveal a cause for the reduced expression of the human manganese superoxide dismutase gene in cancer cells. *Oncogene*. 1999, 18(1), 93-102.
 107. Oberley TD, Zhong W, Szveda II, Oberley IW. Localization of an-

- tioxidant enzymes and oxidative damage products in normal and malignant prostate epithelium. *Prostate*. 2000, 44(2), 144-155.
108. Oberley TD, Oberley LW. Antioxidant enzyme levels in cancer. *Histol Histopathol*, 1997, 12(2), 525-535.
109. Mantovaci G, Maccio A, Ferrel I, et al. Quantitative evaluation of oxidative stress, chronic inflammation indices and leptin in cancer patients: correlation with stage and performance status. *Int J Cancer*. 2002, 98(1), 84-91.
110. Menon SG, Sarsour EH, Spitz DR, et al. Redox regulation of the G1 to S phase transition in the mouse embryo fibroblast cell cycle. *Cancer Res*. 2003, 63(9), 2109-2117.
111. Powis G, Mustacich D, Coon A. The role of the redox protein thioredoxin in cell growth and cancer. *Free Radic Biol Med*. 2000, 29(3-4), 312-322.
112. Menon SG, Sarsour EH, Spitz DR, et al. Redox regulation of the G1 to S phase transition in the mouse embryo fibroblast cell cycle. *Cancer Res*. 2003, 63(9), 2109-2117.
113. Rhee SG. Redox signaling: hydrogen peroxide as intracellular messenger. *Experimental and Molecular Medicine*. 1999, 31(2), 53-59.
114. Okamoto K, Toyokuni S, Uchida K, et al. Formation of 8-hydroxy-2'-deoxyguanosine and 4-hydroxy-2-nonenal-modified proteins in human renal-cell carcinoma. *Int J Cancer*. 1994, 58(6), 825-829.
115. Portakal O, Ozkaya O, Erden Inal M, et al. Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. *Clin Biochem*. 2000, 33(4), 279-284.
116. Toyokuni S, Okamoto K, Yodoi J, Hiai H. Persistent oxidative stress in cancer. *FEBS Lett*. 1995, 358(1), 1-3.
117. Loo G. Redox-sensitive mechanisms of phytochemical-mediated inhibition of cancer cell proliferation (review). 2003, 14(2), 64-73.
118. He T, Weintraub NI, Goswami PC, et al. Redox factor-1 contributes to the regulation of progression from G0/G1 to S by PDGF in vascular smooth muscle cells. *Am J Physiol Heart Circ Physiol*. 2003, 285(2), 11804-812.
119. Burdon RH, Rice Evans C. Free radicals and the regulation of mammalian cell proliferation. *Free Radic Res Commun*. 1998, 6(6), 345-358.
120. Bostwick DG, Alexander EE, Singh R, et al. Antioxidant enzyme expression and reactive oxygen species damage is prostatic intraepi-

- thelial neoplasia and cancer. *Cancer*. 2000, 89(1), 123-134.
121. Tanaka T, Iwasa Y, Kondo S, et al. High incidence of allelic loss on chromosome 5 and inactivation of p151NK4B and p161NK4A tumor suppressor genes in oxystress-induced renal cell carcinoma in rats. *Oncogene*. 1999, 18(25), 3793-3797.
 122. Hiroyasu M, Ozeki M, Konda H, et al. Specific allelic loss of p16 INK4A tumor suppressor gene after weeks of iron-mediated oxidative damage during rat renal carcinogenesis. *American Journal of Pathology*. 2002, 160, 419-424.
 123. Shackelford RE, Kaufmann WK, Paules RS. Oxidative stress and cell cycle checkpoint function. *Free Radic Biol Med*. 2000, 28(9), 1387-1404.
 124. Shackelford RE, Kaufmann WK, Paules RS. Cell cycle control, checkpoint mechanisms, and genotoxic stress. *Environ Health Perspect*. 1999, 107(Suppl 1), 5-24.
 125. Burdon RH. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. *Free Radic Biol Med*. 1995, 18(4), 775-794.
 126. Burkitt MJ, Gilbert BC. Model studies of the iron-catalysed Haber-Weiss cycle and the ascorbate-driven Fenton reaction. *Free Radic Res Commun*. 1990, 10(4-5), 265-280.
 127. Valko M, Morris H, Cronin MT. Metals, toxicity and oxidative stress. *Curr Med Chem*. 2005, 12(10), 1161-1208.
 128. Samuni A, Aronovitch J, Godinger D, et al. On the cytotoxicity of vitamin C and metal ions. A site-specific Fenton mechanism. *Eur J Biochem*. 1983, 137(1-2), 119-124.
 129. Jones W, Li X, Qu ZC, et al. Uptake, recycling and antioxidant actions of alpha-lipoic acid in endothelial cells. *Free Radic Biol Med*. 2002, 33(1), 83-93.
 130. Hayflick I. The limited in vitro lifetime of human diploid cell strains. *Exp Cell Res*. 1965, 37, 614-636.
 131. Shay JW, Wright WE. Hayflick, his limit, and cellular ageing. *Nature Reviews. Molecular Cell biology*. 2000, 1, 72-76.
 132. Kim NW, Piatyszeck MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. *Science*. 1994, 266(5193), 2011-2015.
 133. Hochachka PW, Rupert JI, Goldenberg I, et al. Going malignant: the hypoxia-cancer connection in the prostate. *Bioessays*. 2002, 24(8), 749-757.
 134. Gatenby RA, Gawlinski ET. The glycolytic phenotype in carcino-

- genesis and tumor invasion: insights through mathematical models. *Cancer Res.* 2003, 63(14), 3847-3854.
135. Gatenby RA. Population ecology issues in tumor growth. *Cancer Res.* 1991, 51(10), 2542-2547.
136. Wilson EO. *The Diversity of Life.* W.W. Norton, New York, 1967.
137. Leather SR, Helden AJ. Roundabouts: our neglected nature reverse? *Biologist.* 2005, 52(2), 102-106.
138. Wayt Gibbs W. Roots of cancer. *Scientific American.* 2003, 289, 56-65.
139. Hahn WC, Counter CM, Lundberg AS, et al. Creation of human tumor cells with defined genetic elements. *Nature.* 1999, 400(6743), 464-468. Comment in *Nature.* 400(6743), 401-402.
140. Kacser H, Burns JA. The molecular basis of dominance. *Genetics.* 1981, 97(3-4), 639-666.
141. Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. *Annals of Internal Medicine.* 2003, 138, 560-570.
142. Mates JM, Sanchez-Jimenez FM. Role of reactive oxygen species in apoptosis implications for cancer therapy. *Int J Biochem Cell Biol,* 2000, 32(2), 157-170.
143. Gottlish TM, Oren M. p53 and apoptosis. *Semin Cancer Biol.* 1998, 8, 359-368.
144. Buzek J, Latonen L, Kurki S, et al. Redox state of tumor suppressor p53 regulates its sequence-specific DNA binding in DNA-damaged cells by cysteine 277. *Nucleic Acids Res.* 2002, 2340-2348.
145. Meplan C, Richard MJ, Hainaut P. Redox signaling and transition metals in the control of the p53 pathway. *Biochem Pharmacol.* 2000, 59(1), 25-33.
146. Parks D, Bolinger R, Mann K. Redox state regulates binding of p53 to sequence-specific DNA, but not to non-specific or mismatched DNA. *Nucleic Acids Res.* 1997, 25(6), 1289-1295.
147. Johnson TM, Yu ZX, Ferrans VJ, et al. Reactive oxygen species are downstream mediators of p53-dependent apoptosis. *Proc Natl Acad Sci USA.* 1996, 93(21), 11848-11852.
148. Polyak K, Xia Y, Zweier JL, et al. A model for p53-induced apoptosis. *Nature.* 1997, 389(6648), 300-305. Comment, *Nature* 1997, 389(6648), 237-238.
149. Li PF, Dietz R, von Harsdorf R. p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cyto-

- chrome c-independent apoptosis blocked by Bel-2. *EMBO J.* 1999, 18, 6027-60-36.
150. Johnson TM, Yu ZX, Ferrans VJ, et al. Reactive oxygen species are downstream mediators of p53-dependent apoptosis. *Proc Natl Acad Sci USA.* 1996, 93(21), 11848-11852.
151. Brash DE, Havre PA. New cancers for antioxidants. *PNAS.* 2002, 99(22), 13969-13971.
152. Jayaraman L, Murthy KG, Zhu C, et al. Identification of redox/repair protein Ref-1 as a potent activator of p53. *Genes Dev.* 1997, 11, 558-570.
153. Rainwater R, Parks D, Anderson ME, et al. Role of cysteine residues in regulation of p53 function. *Mol Cell Biol.* 1995, 15(7), 3892-3903.
154. Hainaut P, Milner J. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. *Cancer Res.* 1993, 53, 4469-4473.
155. Merwin JR, Mustacich DJ, Muller EGD, et al. Reporter gene transactivation by human p53 is inhibited in thioredoxin reductase null yeast by a mechanism associated with thioredoxin oxidation and independent of changes in the redox state of glutathione. *Carcinogenesis.* 2002, 23(10), 1609-1616.
156. Moss RW. *Antioxidants and Cancer.* Equinox Press, PA. USA, 2000.
157. King RJB. *Cancer Biology,* Pearson Education, Prentice Hall, Essex, England, 2000.
158. Hockenberry D, Nunez G, Milliman C, et al. Bel-2 is an inner mitochondrial membrane protein that blocks programmed cell death. *Nature.* 1990, 348, 334-336.
159. Kelekar A, Thompson CB. Bel-2 family proteins: the role of the BH3 domain in apoptosis. *Trends Cell Biol.* 1998, 8, 324-330.
160. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bel-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. *Cell.* 1993, 74, 609-619.
161. Mirkovic N, Voehringer DW, Story MD, et al. Resistance to radiation-induced apoptosis in Bel-2-expressing cells is reversed by depleting cellular thiols. *Oncogene.* 1997, 15, 1461-1470.
162. Voehringer DW, McConkey DJ, McDonnell TJ, et al. Bel-2 expression causes redistribution of glutathione to the nucleus. *Proc Natl Acad Sci USA.* 1998, 95, 2956-2960.
163. Preston-Martin S, Pike MC, Ross RK, et al. Increased cell division as a cause of human cancer. *Cancer Res.* 1990, 50(23), 7415-7421.

164. Meraldi P, Honda R, Nigg EA. Aurora kinases link chromosome segregation and cell division to cancer susceptibility. *Curr Opin Genet Dev.* 2004, 14(1), 29-36.
165. Pihan GA, Purohit A, Wallace J, et al. Centrosome defects and genetic instability in malignant tumors. *Cancer Res.* 1998, 58(17), 3974-3985.
166. Ghadimi BM, Sackett DI, Difilippantonio MJ, et al. Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations. *Genes Chromosomes Cancer.* 2000, 27(2), 183-190.
167. Saunders WS, Shuster M, Huang X, et al. Chromosomal instability and cytoskeletal defects in oral cancer cells. *Proc Natl Acad Sci U S A.* 2000, 97(1), 303-308.
168. Bartek J, Lukas J, Barkova J. Perspective: defects in cell cycle control and cancer. *J Pathol.* 1999, 187(1), 95-99.
169. Nigg EA. Centrosome aberrations: cause or consequence of cancer progression? *Nat Rev Cancer.* 2002, 2(11), 815-825.
170. Kramer A, Ho AD. Centrosome aberrations and cancer. *Oncologie.* 2001, 24(6), 538-544.
171. Duesberg P, Rausch C, Rasnick D, Hehlmann R. Genetic instability of cancer cells is proportional to their degree of aneuploidy. *Proc Natl Acad Sci U S A.* 1998, 95(23), 13692-13697.
172. Li R, Sonik A, Stindl R, Rasnick D, Duesberg P. Aneuploidy vs. gene mutation hypothesis of cancer: Recent study claims mutation but is found to support aneuploidy. *Proc Natl Acad Sci U S A.* 2000, 97(7), 3236-3241.
173. Sen S. Aneuploidy and cancer. *Curr Opin Oncol.* 2000, 12(1), 82-88.
174. Mitelman F, Mertens F, Johansson B. A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. *Nat Genet.* 1997, Apr;15 Spec No:417-474.
175. Gebbart E, Liehr T. Patterns of genomic imbalances in human solid tumors (Review). *Int J Oncol.* 2000, 16(2), 383-389.
176. Atkin NB, Baker MC. Are human cancers ever diploid – or often trisomic? Conflicting evidence from direct preparations and cultures. *Cytogenet Cell Genet.* 1990, 53(1), 58-60.
177. Loeb KR, Loeb LA. Significance of multiple mutations in cancer. *Carcinogenesis.* 2000, 21(3), 379-385.
178. Andreassen PR, Martineau SN, Margolis RI. Chemical induction

- of mitotic checkpoint override in mammalian cells results in aneuploidy following a transient tetraploid state. *Mutat Res.* 1996, 372(2), 181-184.
179. Tucker JD, Preston RJ. Chromosome aberrations, micronuclei, aneuploidy, sister chromatid exchanges, and cancer risk assessment. *Mutat Res.* 1996, 365(1-3), 147-159.
180. Oshimura M, Barret JC. Chemically induced aneuploidy in mammalian cells: mechanisms and biological significance in cancer. *Environ Mutagen.* 1986, 8(1), 129-159.
181. Galloway SM, Buckton KE. Aneuploidy and ageing: chromosome studies on a random sample of the population using G-banding. *Cytogenet Cell Genet.* 1978, 20(1-6), 78-95.
182. Li R, Sonik A, Stindl R, Rasnick D, Duesberg P. Aneuploidy vs. gene mutation hypothesis of cancer: Recent study claims mutation but is found to support aneuploidy. *Proc Natl Acad Sci U S A.* 2000, 97(7), 3236-3241.
183. Duesberg P, Stindl R, Hehlmann R. Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy. *Proc Natl Acad Sci U S A.* 2000, 97(26), 14295-14300.
184. Rasnick D, Duesberg PH. How aneuploidy affects metabolic control and causes cancer. *Biochem J.* 1999, 340(3), 621-630.
185. Duesberg P, Rasnick D. Aneuploidy, the somatic mutation that makes cancer a species of its own. *Cell Motil Cytoskeleton.* 2000, 47(2), 81-107.
186. Li R, Yerganian G, Duesberg P, et al. Aneuploidy correlated 100% with chemical transformation of Chinese hamster cells. *Proc Natl Acad Sci U S A.* 1997, 94(26), 14506-14511.
187. Duesberg P, Li R, Rasnick D, et al. Aneuploidy precedes and segregates with chemical carcinogenesis. *Cancer Genet Cytogenet.* 2000, 119(2), 89-93.
188. Beard J. Embryological aspects and etiology of carcinoma. *The Lancet.* 1902, June 21, 1758-1761.
189. Westerman BA, Poutsma A, Maruyama K, et al. The proneural genes NEUROD1 and NEUROD2 are expressed during human trophoblast invasion. *Mech Dev.* 2002, 113(1), 85-90.
190. Southall PJ, Boxer GM, Bagshawe KD, et al. Immunohistological distribution of 5T4 antigen in normal and malignant tissues. *Br J Cancer.* 1990, 61(1), 89-95.

191. Yamashita K, Nakamuta T, Shimizu T, Ohno H. Monoclonal antibodies to human choriocarcinoma. *Am J Reprod Immunol Microbiol.* 1986, 11(4), 130-134.
192. Westerman BA, Poutsma A, Maruyama K, et al. The proneural genes NEUROD1 and NEUROD2 are expressed during human trophoblast invasion. *Mech Dev.* 2002, 113(1), 85-90.
193. Gurchot C. The trophoblast theory of cancer (John Beard, 1857-1924) revisited. *Oncology.* 1975, 31(5-6), 310-333.
194. Makino Y, Sakagami H, Takeda M. Induction of cell death by ascorbic acid derivatives in human renal carcinoma and glioblastoma celllines. *Anticancer Res.* 1999, 19, 3125-3313.
195. Smith J, Ladi E, Mayer-Proschel M, Noble M. Redox state is a central modulator of the balance between self-renewal and differentiation in a dividing glial precursor cell. *Proc Natl Acad Sci U S A.* 2000, 97(18), 10032-10037.
196. Esposito F, Agosti V, Morrone G, et al. Inhibition of the differentiation of human myeloid cell lines by redox changes induced through glutathione depletion. *Biochem J.* 1994, 301(3), 649-53.
197. Gonzalez MJ, Miranda-Massari JR, Mora EM, et al. Orthomolecular oncology: a mechanistic view of ascorbate's chemotherapeutic activity. *PR Health Sci J.* 2002, 21(1), 39-41.
198. Warburg O. *The Catalytic Activity of Living Tissues.* Springer, Berlin, 1938.
199. Weber G. *Enzymology of cancer cells.* *N Engl J Med.* 1977, 296, 541-558.
200. Warburg O. *Metabolism of tumors.* Arnold Constable, London, 1930.
201. Con CF, Con GT. The carbohydrate metabolism of tumours. *J Bioi Chem.* 1925, 65, 397-405.
202. Warburg O. A review. *Science.* 1956, 123, 309-315.
203. Szent-Gyorgyi A. The living state and cancer. In: *Submolecular Biology and Cancer, Ciba Foundation Symposium 67, Excerpta Medica, New York, 1960.*
204. Gonzalez MJ, Miranda-Massari JR, Mora EM, et al. Orthomolecular oncology review: ascorbic acid and cancer 25 years later. *Integr Cancer Ther.* 2005, 4(1), 32-44.
205. Gonzalez MJ, Miranda-Massari JR, Mora EM, et al. Orthomolecular oncology: a mechanistic view of ascorbate's chemotherapeutic activity. *PR Health Sci J.* 2002, 21(1), 39-41.

206. Green S. Oxygenation Therapy: Unproven Treatments for Cancer and AIDS. *Scientific Review of Alternative Medicine*, Spring/Summer, 1998.
207. Aisenberg A. *The glycolysis and respiration of tumors. A review.* Academic Press, New York, 1961.
208. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. *Cancer Res.* 1989, 49(23), 6449-6465.
209. Kung AL, Wang S, Klco JM, et al. Suppression of tumor growth through disruption of hypoxia-inducible transcription. *Nature Medicine.* 2000, 6(12), 1335-1340.
210. Koong AC, Denco NC, Hudson KM, et al. Candidate genes for hypoxic tumor phenotype. *Cancer Res.* 2000, 60, 883-887.
211. Allen KG, Venkatraj VS. Oxidants and antioxidants in development and differentiation. *J Nutr.* 1992, 122, 631-635.
212. Gonzalez MJ, Schemmel RA, Dugan L, et al. Dietary fish oil inhibition of human breast carcinoma growth: a function of increased lipid peroxidation. *Lipids.* 1993, 28, 827-832.
213. Helmlinger G, Yuan F, Dellian M, Jain RK. Interstitial pH and pO₂ gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. *Nat Med.* 1997, 3(2), 177-182.
214. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. *Cancer Res.* 1998, 58(7), 1408-1416.
215. Freiberg RA, Green SL, Giaccia AJ. *Hypoxia and cell cycle, Cell Cycle Checkpoints and Cancer*, Ed Blagosklonny, MV Landes Bioscience, Georgetown, Texas, 2002.
216. Liotta LA, Kohn EC. The microenvironment of the tumor-host interface. *Nature.* 2001, 411, 375-379.
217. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. *Cancer Res.* 1998, 58(7), 1408-1416.
218. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. *Nature.* 2000, 407(6801), 249-257.
219. Schwickert G, Walenta S, Sundfor K, et al. Correlation of high lactate levels in human cervical cancer with incidence of metastasis. *Cancer Res.* 1995, 55(21), 4757-4759.
220. Huso DL, Dillehay L, Cheong I, et al. Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. *PNAS.* 2003, 100(25),

- 15083-15088.
221. Jain RK, Forbes NS. Can engineered bacteria help control cancer? PNAS. 2001, 98(26), 14748-14750.
222. Rofstad EK. Microenvironment-induced cancer metastasis. Int J Rad Biol. 2000, 76(5), 589-605.
223. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989, 49(16), 4373-4384.
224. Schwickert G, Walenta S, Sundfor K, et al. Correlation of high lactate levels in human cervical cancer with incidence of metastasis. Cancer Res. 1995, 55(21), 4757-4759.
225. Kallinowski F, Vaupel P, Runkel S, et al. Glucose uptake, lactate release, ketone body turnover, metabolic micromilieu, and pH distributions in human breast cancer xenografts in nude rats. Cancer Res. 1988, 48(24), 7264-7272.
226. Barefoot RR, Reich CM. The Calcium Factor: The Scientific Secret of Health and Youth. Bokar Consultants, Wickenburg, Arizona, 2002.
227. Barefoot RR. Death by Diet. Deonna Enterprises, Wickenburg, Arizona, 2002.
228. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994, 91(9), 4082-4085.
229. Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol. 1998, 55(11), 1827-1834.
230. Tseng S, Pak G, Washenik K, et al. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol. 1996, 35(6), 969-979.
231. Ehrenpreis ED, Kane SV, Cohen LB, et al. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology. 1999, 117(6), 1271-1277.
232. Calabrese I, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med. 2000, 108(6), 487-495.
233. Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, et al. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS. 1996, 10(13), 1501-1507.
234. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. New Engl J Med. 1999, 341(21), 1565-1571.

235. Fine HA, Figg WD, Jacckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. *J Clin Oncol.* 2000, 18(4), 708-715.
236. Parman T, Wiley MJ, Wells PG. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. *Nat Med.* 1999, 5(5), 582-585.
237. Sauer H, Gunther J, Hescheler J, Wartenberg M. Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals. *Am J Pathol.* 2000, 156(1), 151-158.
238. Wells PG, Kim PM, Laposa RR, et al. Oxidative damage in chemical teratogenesis. *Mutat Res.* 1997, 396(1-2), 65-78.
239. Hansen JM, Harris KK, Philbert MA, Harris C. Thalidomide modulates nuclear redox status and preferentially depletes glutathione in rabbit limb versus rat limb. *J Pharmacol Exp Ther.* 2002, 300(3), 768-776.
240. Brown NS, Jones A, Fujiyama C, et al. Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. *Cancer Res.* 2000, 60(22), 6298-6302.
241. Chandel NS, McClintock DS, Feliciano CE, et al. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1 alpha during hypoxia: a mechanism of O₂ sensing. *J Biol Chem.* 2000, 275(33), 25130-25138.
242. Richard DE, Berra E, Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1 alpha in vascular smooth muscle cells. *J Biol Chem.* 2000, 275(35), 26765-26771.
243. Brown NS, Bicknell R. Hypoxia and oxidative stress in breast cancer: Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. *Breast Cancer Res.* 2001, 3(5), 323-327.
244. Polytarchou C, Papadimitriou E. Antioxidants inhibit angiogenesis in vivo through down-regulation of nitric oxide synthase expression and activity. *Free Radical Research.* 2004, 38(5), 501-508.
245. Ashino H, Shimamura M, Nakajima H, et al. Novel function of ascorbic acid as an angiostatic factor. *Angiogenesis.* 2003, 6(4), 259-269.
246. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. *Nat Med.* 2003, 9(6), 677-684.
247. Knowles HJ, Raval RR, Harris AI, Ratcliffe PJ. Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. *Cancer Res.* 2003, 63, 1764-1768.

248. Koike T, Kimura N, Miyazaki K, et al. Hypoxia induces adhesion molecules on cancer cells: a missing link between Warburg effect and induction of selectin-ligand carbohydrates. *PNAS*, 2004, 101(21), 8132-8137.
249. Kannagi R. Molecular mechanism for cancer-associated induction of sialyl Lewis X and sialyl Lewis A expression – The Warburg effect revisited. *Glycoconj J*. 2004, 20(5), 353-364.
250. Kimura N, Mitsuoka C, Kanamori A, et al. Reconstitution of functional L-selectin ligands on a cultured human endothelial cell line by cotransfection of alpha-1-3-fucosyltransferase VII and newly cloned GlcNAc6-sulfotransferase cDNA. *Proc Natl Acad Sci U S A*. 1999, 96(8), 4530-4535.
251. King RJB. *Cancer Biology*. Pearson Education. Prentice Hall, Essex, England, 2000.
252. Jelinek F. Spontaneous tumours in guinea pigs. *Acta Vet Brno*. 2003, 72, 221-228.
253. Nakanishi M, Kuwamura M, Ueno M, et al. Pulmonary adenocarcinoma with osteoblastic bone metastases in a cat. *J Small Animal Practice*. 2003, 44(10), 464-466.
254. Labelle P, De Cock HEV. Metastatic tumors to the adrenal glands in domestic animals. *Vet Pathol*. 2005, 42, 52-58.
255. King RJB. *Cancer Biology*. Pearson Education. Prentice Hall, Essex, England, 2000.
256. Egner PA, Kensler TW. Effects of a biomimetic superoxide dismutase on complete and multistage carcinogenesis in mouse skin. *Carcinogenesis*. 1985, 6, 1167-1172.
257. Dermime S, Armstrong A, Hawkins RE, Stern PL. Cancer vaccines and immunotherapy. *British Medical Bulletin*. 2002, 62, 149-162.
258. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. *Proc Natl Acad Sci*. 1975, 72, 3666-3670.
259. Malik STA, Griffin DB, Fiers W, Balkwill FR. Paradoxical, effects of tumour necrosis factor in experimental ovarian cancer. *Int J Cancer*. 1989, 44, 918-925.
260. Malik STA, Naylor S, East N, et al. Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. *Eur J Cancer*. 1990, 26, 1031-1034.
261. Roberts RA, Kimber I. Cytokines in non-genotoxic hepatocarcinogenesis. *Carcinogenesis*. 1999, 20, 1397-1401.

262. Erickson SL, de Sauvage FJ, Kikly K, et al. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. *Nature*. 1994, 372(6506), 560-563.
263. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? *Lancet*. 2001, 357, 539-545.
264. Brigati C, Noonan DM, Albini A, Benelli R. Tumors and inflammatory infiltrates: friends or foes? *Clinical and Experimental Metastasis*. 2002, 19(3), 247-258.
265. Dvorak HF. Tumors: wounds that do not heal. *N Engl J Med*. 1986, 315, 1650-1659.
266. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? *Lancet*. 2001, 357, 539-545.
267. Tricot G. New insights into role of microenvironment in multiple myeloma. *Lancet*. 2000, 355, 248-250.
268. Thun MJ, Namboodiri MM, Calle EE, et al. Aspirin use and risk of fatal cancer. *Cancer Res*. 1993, 53, 1322-1327.
269. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case control study in general practice research database. *BMJ*. 2000, 320, 1642-1646.
270. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. *Cancer Res*. 1996, 56, 4566-4569.
271. Haghnegahdar H, Du J, Wang D, et al. The tumorigenic and angiogenic effects of MGSSA/GRO proteins in melanoma. *J Leukoc Biol*. 2000, 67, 53-62.
272. Wang JM, Chertov O, Proost P, et al. Purification and identification of chemokines potentially involved in kidney-specific metastasis by a murine lymphoma variant: induction of migration and NFkappaB activation. *Int J Cancer*. 1998, 75(6), 900-907.
273. Owyang SY, Luther J, Kao JY. *Helicobacter pylori*: beneficial for most? Expert review of gastroenterology & hepatology. *Dec 2011*;5(6):649-651.
274. Chen Y, Blaser MJ. Inverse associations of *Helicobacter pylori* with asthma and allergy. *Archives of internal medicine*. *Apr 23 2007*;167(8):821-827.
275. McNeil C. *Helicobacter pylori*: good side complicates efforts to combat bad side. *Journal of the National Cancer Institute*. *Dec 17 2008*;100(24):1748-1750.

276. Malfertheiner P, Selgrad M. Helicobacter pylori infection and current clinical areas of contention. *Current opinion in gastroenterology*. Nov 2010;26(6):618-623.
277. Graham DY. History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer. *World J Gastroenterol*. May 14 2014;20(18):5191-5204.
278. Blaser MJ. Helicobacter pylori and gastric diseases. *BMJ*. 1998;316(7143):1507-1510.
279. Blaser MJ, Chen Y, Reibman J. Does Helicobacter pylori protect against asthma and allergy? *Gut*. 2008;57(5):561-567.
280. Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. *J Cell Sci*. 2012;125(pt 23):5591-5596.
281. Li H, Fan X, Houghton J. Tumor microenvironment: the role of the tumor stroma in cancer. *J Cell Biochem*. 2007;101(4):805-815.
282. Wang M, Zhao J, Zhang L, et al. Role of tumor microenvironment in tumorigenesis. *J Cancer*. 2017;8(5):761-773.
283. Fridman W, Pages F, Sautes-Fridman C. et al. The immune contexture in human tumours: impact on clinical outcome. *Nat Rev Cancer*. 2012, 12, 298–306.
284. Yoon NK, Maresh EL, Shen D, et al. Higher levels of GATA3 predict better survival in women with breast cancer. *Hum. Pathol*. 2010, 41, 1794-1801.
285. Lv L, Pan K, Li XD, et al. The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma. *PLoS ONE*. 2011, 6, e18219.
286. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. *J Clin Oncol*. 2006 Dec 1;24(34):5373-80.
287. Curiel T., Coukos G, Zou L. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. *Nat Med*. 2004, 10, 942–949.
288. Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. *Clin Cancer Res*. 2006 Sep 15;12(18):5423-34.
289. Coronella JA, Telleman P, Kingsbury GA, et al. Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer. *Cancer Res*. 2001 Nov 1;61(21):7889-99.
290. Milne K, Kobel M, Kalloger SE, et al. Systematic analysis of im-

- mune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. *PLoS One*. 2009 Jul 29;4(7):e6412.
291. Qin Z, Richter G, Schuler T. et al. B cells inhibit induction of T cell-dependent tumor immunity. *Nat Med*. 1998, 4, 627-630.
292. Tachibana T, Onodera H, Tsuruyama T, et al. Increased intratumor V α 24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. *Clin Cancer Res*. 2005 Oct 15;11(20):7322-7.
293. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. *Cell*. 2010 Apr 2;141(1):39-51.
294. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. *Cell*. 2006 Jan 27;124(2):263-6.
295. Kusmartsev S, Nagaraj S, Gabrilovich DI. Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. *J Immunol*. 2005;175(7):4583-4592.
296. Huang B, Pan PY, Li Q, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. *Cancer Res*. 2006 Jan 15;66(2):1123-31.
297. Spaeth EL, Dembinski JL, Sasser AK, et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. *PLoS One*. 2009;4(4):e4992.
298. Nieman K, Kenny H, Penicka C, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. *Nat Med*. 2011, 17, 1498-1503.
299. Carmeliet P, Jain R. Molecular mechanisms and clinical applications of angiogenesis. *Nature*. 2011, 473, 298-307.
300. O'Keefe MB, Devlin AH, Burns AJ, et al. Investigation of pericytes, hypoxia, and vascularity in bladder tumors: association with clinical outcomes. *Oncol Res*. 2008;17(3):93-101.
301. Yonenaga Y, Mori A, Onodera H, et al. Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients. *Oncology*. 2005;69(2):159-66.
302. Swartz M, Lund A. Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity. *Nat Rev Cancer*. 2012, 12, 210-219.

303. Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. *J Cell Sci.* 2010 Dec 15;123(Pt 24):4195-200.
304. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. *Science.* 2011;331(6024):1565-1570.
305. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases – elimination, equilibrium and escape. *Curr Opin Immunol.* 2014;27:16-25.
306. Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. *Clin Cancer Res.* 2015;21(4):687-692.
307. Leonardi GC, Accardi G, Monastero R, Nicoletti F, Libra M. Ageing: from inflammation to cancer. *Immun Ageing.* 2018;15:1.
308. Castro AM, Macedo-de la Concha LE, Pantoja-Meléndez CA. Low-grade inflammation and its relation to obesity and chronic degenerative diseases [in Spanish]. *Rev Med Hosp Gen (Mex).* 2017;80(2):101-105.
309. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. *J Gerontol A Biol Sci Med Sci.* 2014;69(suppl 1):S4-S9.
310. Vyas D, Laput G, Vyas AK. Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis. *Onco Targets Ther.* 2014;7:1015-1023.
311. Taniguchi K, Karin M. NF- κ B, inflammation, immunity and cancer: coming of age. *Nat Rev Immunol.* 2018;18(5):309-324.
312. Panday A, Inda ME, Bagam P, et al. Transcription factor NF- κ B: an update on intervention strategies. *Arch Immunol Ther Exp (Warsz).* 2016;64(6):463-483.
313. de Castro Barbosa ML, da Conceicao RA, Fraga AGM, et al. NF- κ B Signaling Pathway Inhibitors as Anticancer Drug Candidates. *Anti-cancer Agents Med Chem.* 2017;17(4):483-490.
314. Comalada M, Camuesco D, Sierra S, et al. In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF- κ B pathway. *Eur J Immunol.* 2005;35(2):584-592.
315. Samykutty A, Shetty AV, Dakshinamoorthy G, et al. Piperine, a bioactive component of pepper spice exerts therapeutic effects on androgen dependent and androgen independent prostate cancer cells. *PLoS One.* 2013;8(6):e65889.
316. Chopan M, Littenberg B. The association of hot red chili pepper

- consumption and mortality: a large population-based cohort study. *PLoS One*. 2017;12(1):e0169876.
317. Agbaria R, Gabarin A, Dahan A, Ben-Shabat S. Anticancer activity of *Nigella sativa* (black seed) and its relationship with the thermal processing and quinone composition of the seed. *Drug Des Devel Ther*. 2015;9:3119-3124.
318. Majdalawieh AF, Fayyad MW, Nasrallah GK. Anti-cancer properties and mechanisms of action of thymoquinone, the major active ingredient of *Nigella sativa*. *Crit Rev Food Sci Nutr*. 2017;57(18):3911-3928.
319. Oliviero M, Romilde I, Beatrice MM, et al. Evaluations of thyme extract effects in human normal bronchial and tracheal epithelial cell lines and in human lung cancer cell line. *Chem Biol Interact*. 2016;256:125-133.
320. Kunnumakkara AB, Sailo BL, Banik K, et al. Chronic diseases, inflammation, and spices: how are they linked? *J Transl Med*. 2018;16(1):14.
321. Tozser J, Benko S. Natural compounds as regulators of NLRP3 inflammasome-mediated IL-1 β production. *Mediators Inflamm*. 2016;2016:5460302.
322. Ren Z, Wang L, Cui J, et al. Resveratrol inhibits NF- κ B signaling through suppression of p65 and I κ B kinase activities. *Pharmazie*. 2013;68(8):689-694.
323. Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. *Biochem Pharmacol*. 2011;82(12):1807-1821.
324. Cruz-Correa M, Shoskes DA, Sanchez P, et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. *Clin Gastroenterol Hepatol*. 2006;4(8):1035-1038.
325. Bishop KS, Ferguson LR. The interaction between epigenetics, nutrition and the development of cancer. *Nutrients*. 2015;7(2):922-947.
326. Timp W, Feinberg AP. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. *Nat Rev Cancer*. 2013;13(7):497-510.
327. Schnekenburger M, Diederich M. Epigenetics offer new horizons for colorectal cancer prevention. *Curr Colorectal Cancer Rep*. 2012;8(1):66-81.
328. Shukla S, Meeran SM, Katiyar SK. Epigenetic regulation by selected dietary phytochemicals in cancer chemoprevention. *Cancer Lett*. 2014;355(1):9-17.
329. Lee EY, Muller WJ. Oncogenes and tumor suppressor genes. *Cold*

- Spring Harb Perspect Biol. 2010;2(10):a003236.
330. Parrales A, Iwakuma T. Targeting oncogenic mutant p53 for cancer therapy. *Front Oncol.* 2015;5:288.
331. Das L, Vinayak M. Long term effect of curcumin in restoration of tumour suppressor p53 and phase-II antioxidant enzymes via activation of Nrf2 signalling and modulation of inflammation in prevention of cancer. *PLoS One.* 2015;10(4):e0124000.
332. Boyanapalli SS, Kong AT. "Curcumin, the king of spices": epigenetic regulatory mechanisms in the prevention of cancer, neurological, and inflammatory diseases. *Curr Pharmacol Rep.* 2015;1(2):129-139.
333. Hardy TM, Tollefsbol TO. Epigenetic diet: impact on the epigenome and cancer. *Epigenomics.* 2011;3(4):503-518.
334. Gupta K, Thakur VS, Bhaskaran N, et al. Green tea polyphenols induce p53-dependent and p53-independent apoptosis in prostate cancer cells through two distinct mechanisms. *PLoS One.* 2012;7(12):e52572.
335. Thakur VS, Gupta K, Gupta S. Green tea polyphenols increase p53 transcriptional activity and acetylation by suppressing class I histone deacetylases. *Int J Oncol.* 2012;41(1):353-361.
336. Dammann RH, Richter AM, Jimenez AP, Woods M, Kuster M, Witharana C. Impact of natural compounds on DNA methylation levels of the tumor suppressor gene RASSF1A in cancer. *Int J Mol Sci.* 2017;18(10):2160.
337. Pan MH, Lai CS, Wu JC, Ho CT. Epigenetic and disease targets by polyphenols. *Curr Pharm Des.* 2013;19(34):6156-6185.
338. Bishop KS, Ferguson LR. The interaction between epigenetics, nutrition and the development of cancer. *Nutrients.* 2015;7(2):922-947.

ΜΕΡΟΣ VI

1. Smith RA, Mettlin CJ, Davis KJ, Eyre H. American Cancer Society guidelines for the early detection of cancer. *CA Cancer J Clin.* 2000, 50(1), 34-49.
2. Miller BA, Feuer EJ, Hankey BF. The increasing incidence of breast cancer since 1982: relevance of early detection. *Cancer Causes Control.* 1991, 2(2), 67-74.
3. Flehinger BJ, Kimmel M, Melamed MR. The effect of surgical treat-

- ment on survival from early lung cancer. Implications for screening. *Chest*. 1992, 101, 1013-1018.
4. Johansson JE, Adami HO, Andersson SO, et al. High 10-year survival rate in patients with early, untreated prostatic cancer. *JAMA*. 1992, 267(16), 2191-2196.
 5. Johansson JE, Holmberg L, Johansson S, et al. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. *JAMA*. 1997, 277(6), 467-471.
 6. Albersen PC, Fryback DG, Storer BE, et al. Long-term survival among men with conservatively treated localized prostate cancer. *JAMA*, 1995, 274(8), 626-631.
 7. Johansson JE, Holmberg L, Johansson S, et al. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. *JAMA*. 1997, 277(6), 467-471.
 8. Chodak, G., Warren, K. Watchful waiting for prostate cancer: a review article. *Prostate Cancer Prostatic Dis*, 2006, 9, 25–29.
 9. Raffle AE, Alden B, Quinn M, et al. Outcomes of screening to prevent cancer: analysis of cumulative incidence of cervical abnormality and modelling of cases and deaths prevented. *BMJ*. 2003, 326(7395), 901.
 10. Sasieni PD. Outcomes of screening to prevent cancer: think of screening as insurance. *BMJ*. 2003, 327(7405), 50.
 11. Gigerenzer G. *Calculated risks: how to know when numbers deceive you*. Simon & Schuster. New York. 2003.
 12. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per millilitre. *NEJM*. 2004, 50(22), 2239-2246.
 13. Gigerenzer G. *Calculated risks: how to know when numbers deceive you*. Simon & Schuster. New York. 2003.
 14. Keeteh DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. *The Journal of Urology*. 1994, 151(6), 1571-1574.
 15. Gigerenzer G. *Calculated risks: how to know when numbers deceive you*. Simon & Schuster. New York. 2003.
 16. Lafata JE, Simpkins J, Lamerato L, et al. The economic impact of false-positive cancer screens. *Cancer Epidemiol Biomarkers Prev*. 2004, 13(12), 2126-2132.
 17. Moss RW. *Questioning Chemotherapy*. Equinox Press, New York. 2000.
 18. Moss RW. *The Cancer Industry*. Equinox Press, New York. 1992.

19. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? *JAMA*. 2000, 283(22), 2975-2978.
20. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. *CA Cancer J Clin*. 2001, 51, 15-36.
21. Ries LAG, Eisner MP, Kosary CL. Et al. SEER Cancer Statistics Review, 1975-2001, National Cancer Institute. 2004. https://seer.cancer.gov/archive/csr/1975_2001/
22. Smith RA, von Eschenbach AC, Wender R, et al. American Cancer Society guidelines for the early detection on cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001 – testing for early lung cancer detection. *CA Cancer J Clin*. 2001, 51(1), 38-75.
23. Moss RW. Questioning Chemotherapy. Equinox Press, New York. 2000.
24. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. *N Engl J Med*. 1985, 312(25), 1604-1608.
25. Woodward WA, Strom EA, Tucker SL, et al. Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. *Clin Oncol*. 2003, 21(17), 3244-3248.
26. Simes RJ. Publication bias: the case for an international registry of clinical trials. *J Clin Oncol*. 1986, 4(10), 1529-1541.
27. Dickersin K, Chan S, Chalmers TC, et al. Publication bias and clinical trials. *Control Clin Trials*. 1987, 8(4), 343-353.
28. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. *Lancet*. 1991, 337(8746), 867-872.
29. Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. *BMJ*. 2003, 326(7400), 1189-1192.
30. Healy DT. Transparency and trust: figure for ghost written articles was misquoted. *BMJ*. 2004, 329(7478), 1345.
31. Zuckerman D. Hype in health reporting: 'checkbook science' buys distortion of medical news. *Int J Health Serv*. 2003, 33(2), 383-389.
32. Taylor GJ, Wainwright P. Open label extension studies: research or marketing? *BMJ*. 2005, 331, 572-574.
33. Zajicek G., A New Cancer Hypothesis, *Medical Hypotheses*. 1996. 47,

- 111-115.
34. Good news from the front in the war against cancer, *New York Times*, 26.5.98
 35. Ries L.A.G., et al., *SEER cancer statistics review, 1973-1991: Tables and Graphs*, Bethesda, 1994
 36. Greenberg D.S., *A Critical Look at Cancer Coverage*, *Columbia Journalism Review*, January-February 1975
 37. Griffin E., *World without cancer. The story of vitamin B 17*, 155, 2000
 38. Olson J.D., Riedel E., DeAngelis L.M., *Long-term outcome of low-grade oligodendroglioma and mixed glioma*, *Neurology*, 2000, 1442-1447.
 39. Chowka P.B., *The National Cancer Institute and the Fifty-Year Cover-up*, *East West*, 23, 1978.
 40. Non-small Cell Lung Cancer Collaborative Group. *Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials*. *BMJ*. 1995, 311, 899-909.
 41. Bird NC, Mangnall D, Majeed AW. *Biology of colorectal liver metastases: A review*. *J SurgOncol*. 2006 Jul 1;94(1):68-80.
 42. van der Bij GJ, Oosterling SJ, Beelen RH, et al. *The perioperative period is an underutilized window of therapeutic opportunity in patients with colorectal cancer*. *Ann Surg*. 2009 May;249(5):727-34.
 43. Wagenaar-Miller RA, Gordon L, Matrisian LM. *Matrix metalloproteinases in colorectal cancer: is it worth talking about?* *Cancer Metastasis Rev*. 2004 Jan;23(1-2):119-35.
 44. van der Bij GJ, Oosterling SJ, Beelen RH, et al. *The perioperative period is an underutilized window of therapeutic opportunity in patients with colorectal cancer*. *Ann Surg*. 2009 May;249(5):727-34.
 45. Ben-Eliyahu S. *The promotion of tumor metastasis by surgery and stress: immunological basis and implications for psychoneuroimmunology*. *Brain Behav Immun*. 2003 Feb;17Suppl1S27-S36.
 46. Yamaguchi K, Takagi Y, Aoki S, et al. *Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection*. *Ann Surg*. 2000 Jul;232(1):58-65.
 47. Da Costa ML, Redmond P, Bouchier-Hayes DJ. *The effect of laparotomy and laparoscopy on the establishment of spontaneous tumor metastases*. *Surgery*. 1998 Sep;124(3):516-25.
 48. Shakhar G, Ben-Eliyahu S. *Potential prophylactic measures against*

- postoperative immunosuppression: could they reduce recurrence rates in oncological patients? *Ann Surg Oncol*. 2003 Oct;10(8):972-92.
49. Demicheli R, Valagussa P, Bonadonna G. Does surgery modify growth kinetics of breast cancer micrometastases? *Br J Cancer*. 2001 Aug 17;85(4):490-2.
 50. Dowdall JF, Winter DC, Andrews E, et al. Soluble interleukin 6 receptor (sIL-6R) mediates colonic tumor cell adherence to the vascular endothelium: a mechanism for metastatic initiation? *J Surg Res*. 2002 Sep;107(1):1-6.
 51. Raz A, Lotan R. Endogenous galactoside-binding lectins: a new class of functional tumor cell surface molecules related to metastasis. *Cancer Metastasis Rev*. 1987;6(3):433-52.
 52. Yu LG, Andrews N, Zhao Q, et al. Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. *J Biol Chem*. 2007 Jan 5;282(1):773-81.
 53. ten Kate M, Hofland LJ, van Grevenstein WM, et al. Influence of proinflammatory cytokines on the adhesion of human colon carcinoma cells to lung microvascular endothelium. *Int J Cancer*. 2004 Dec 20;112(6):943-50.
 54. Nangia-Makker P, Hogan V, Honjo Y, et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. *J Natl Cancer Inst*. 2002 Dec 18;94(24):1854-62.
 55. Herberman RB, Ortaldo JR. Natural killer cells: their roles in defenses against disease. *Science*. 1981 Oct 2;214(4516):24-30.
 56. McCoy JL, Rucker R, Petros JA. Cell-mediated immunity to tumor-associated antigens is a better predictor of survival in early stage breast cancer than stage, grade or lymph node status. *Breast Cancer Res Treat*. 2000 Apr;60(3):227-34.
 57. Koda K, Saito N, Takiguchi N, et al. Preoperative natural killer cell activity: correlation with distant metastases in curatively resected colorectal carcinomas. *Int Surg*. 1997 Apr;82(2):190-3.
 58. Da Costa ML, Redmond P, Bouchier-Hayes DJ. The effect of laparotomy and laparoscopy on the establishment of spontaneous tumor metastases. *Surgery*. 1998 Sep;124(3):516-25.
 59. Rosenne E, Shakhar G, Melamed R, et al. Inducing a mode of NK-resistance to suppression by stress and surgery: a potential approach based on low dose of poly I-C to reduce postoperative cancer metas-

- tasis. *Brain Behav Immun*. 2007 May;21(4):395-408.
60. McCulloch PG, MacIntyre A. Effects of surgery on the generation of lymphokine-activated killer cells in patients with breast cancer. *Br J Surg*. 1993 Aug;80(8):1005-7.
 61. Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? *Ann Surg Oncol*. 2003 Oct;10(8):972-92.
 62. Ribatti D. *History of Research on Tumor Angiogenesis*. Springer;2009:9.
 63. Rege TA, Fears CY, Gladson CL. Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy. *NeuroOncol*. 2005 Apr;7(2):106-21.
 64. Baum M, Demicheli R, Hrushesky W, et al. Does surgery unfavourably perturb the "natural history" of early breast cancer by accelerating the appearance of distant metastases? *Eur J Cancer*. 2005 Mar;41(4):508-15.
 65. Folkman J. Fundamental concepts of the angiogenic process. *Curr Mol Med*. 2003 Nov;3(7):643-51.
 66. Pinsolle V, Ravaut A, Baudet J. [Does surgery promote the development of metastasis in melanoma?]. *Ann Chir Plast Esthet*. 2000 Aug;45(4):485-93.
 67. Raymond E. [Tumor angiogenesis inhibitors: media and scientific aspects]. *Presse Med*. 1998 Jul 4-11;27(24):1221-4.
 68. Goldfarb Y, Ben-Eliyahu S. Surgery as a risk factor for breast cancer recurrence and metastasis: mediating mechanisms and clinical prophylactic approaches. *Breast Dis*. 2006-2007;26:99-114.
 69. Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? *Ann Surg Oncol*. 2003 Oct;10(8):972-92.
 70. van der Bij GJ, Oosterling SJ, Beelen RH, et al. The perioperative period is an underutilized window of therapeutic opportunity in patients with colorectal cancer. *Ann Surg*. 2009 May;249(5):727-34.
 71. Baigrie RJ, Lamont PM, Kwiatkowski D, et al. Systemic cytokine response after major surgery. *Br J Surg*. 1992 Aug;79(8):757-60.
 72. Wu FP, Sietses C, von Blomberg BM, et al. Systemic and peritoneal inflammatory response after laparoscopic or conventional colon resection in cancer patients: a prospective, randomized trial. *Dis Colon*

- Rectum. 2003 Feb;46(2):147-55.
73. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. *Cell*. 1998 May 29;93(5):705-16.
 74. Chu J, Lloyd FL, Trifan OC, et al. Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer. *Mol Cancer Ther*. 2003 Jan;2(1):1-7.
 75. Kakiuchi Y, Tsuji S, Tsujii M, et al. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis. *Cancer Res*. 2002 Mar 1;62(5):1567-72.
 76. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. *Cancer Res*. 1999 Mar 1;59(5):987-90.
 77. Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. *Cancer Res*. 1999 Mar 1;59(5):991-4.
 78. Soumaoro LT, Uetake H, Higuchi T, et al. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. *Clin Cancer Res*. 2004 Dec 15;10(24):8465-71.
 79. Yuan A, Yu CJ, Shun CT, et al. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. *Int J Cancer*. 2005 Jul 1;115(4):545-55.
 80. Moss R., *The Cancer industry*, 59-72, 1996
 81. Bush RS, Jenkin RD, Allt WF, et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. *Br J Cancer Suppl*. 1978, 37(3), 302-306.
 82. Beskow C, Agren-Cronqvist AK, Granath F, et al. Pathologic complete remission after preoperative intracavitary radiotherapy of cervical cancer stage Ib and IIa is a strong prognostic factor for long-term survival: analysis of the Radiumhemmet data 1989-1991. *Int J Gynecol Cancer*. 2002, 2(2), 158-170.
 83. Zijlstra JM, Dressel AJ, Mens JW, et al. Radiation therapy in early stage Hodgkin's disease: long-term results and adverse effects. *Hematol J*. 2002, 3(4), 179-184.
 84. Mauch PM, Kalish LA, Marcus KC, et al. Long-term survival in Hodgkin's disease. *Cancer J Sci Am*. 1995, 1(1), 33.
 85. Lavey RS, Eby NL, Prosnitz LR. Impact on second malignancy risk of

- the combined use of radiation and chemotherapy for lymphomas. *Cancer*. 1990, 66(1), 80-88.
86. McTaggart L. Ed., *The cancer handbook. What's really working*, 85-93, 2001
87. Proctor RN., *Cancer wars: How politics shapes what we know and don't know about cancer*, 1995.
88. Gofman J., *Preventing breast cancer*, 6, 1995.
89. Wiernik P.H., Sklarin N.T., Dutcher J.P., Sparano J.A., Greenwald E.S., *Adjuvant radiotherapy for breast cancer as a risk factor for the development of lung cancer*, *Medical Oncology*. 1994, 11, 3, 121-125.
90. Boice JD Jr, Travis LB. *Body wars: effect of friendly fire (cancer therapy)*. *J Natl Cancer Inst*. 1995 May 17;87(10):705-6.
91. Giglio P, Gilbert MR. *Neurologic complications of cancer and its treatment*. *Curr Oncol Rep*. Jan 2010;12(1):50-59.
92. Verma N, Cowperthwaite MC, Burnett MG, Markey MK. *Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies*. *Neuro Oncol*. May 2013;15(5):515-534.
93. Hunter SE, Scher RL. *Clinical implications of radionecrosis to the head and neck surgeon*. *Curr Opin Otolaryngol Head Neck Surg*. 2003 Apr;11(2):103-6.
94. Lee YW, Cho HJ, Lee WH, Sonntag WE. *Whole brain radiation-induced cognitive impairment: pathophysiological mechanisms and therapeutic targets*. *Biomol Ther (Seoul)*. Jul 2012;20(4):357-370.
95. Greene-Schloesser D, Robbins ME, Peiffer AM, et al. *Radiation-induced brain injury: A review*. *Frontiers in oncology*. 2012;2:73.
96. Chapman CH, Nagesh V, Sundgren PC, et al. *Diffusion tensor imaging of normal-appearing white matter as biomarker for radiation-induced late delayed cognitive decline*. *Int J Radiat Oncol Biol Phys*. 2012 Apr 1;82(5):2033-40.
97. Warrington JP, Ashpole N, Csiszar A, et al. *Whole brain radiation-induced vascular cognitive impairment: mechanisms and implications*. *Journal of Vascular Research*. 2013;50(6):445-457.
98. Abayomi OK. *Neck irradiation, carotid injury and its consequences*. *Oral Oncology*. Oct 2004;40(9):872-878.
99. Arthurs E, Hanna TP, Zaza K, et al. *Stroke After Radiation Therapy for Head and Neck Cancer: What Is the Risk?* *Int J Radiat Oncol Biol Phys*. Nov 01 2016;96(3):589-596.
100. Dorresteijn LD, Kappelle AC, Boogerd W, et al. *Increased risk of ischemic stroke after radiotherapy on the neck in patients younger*

- than 60 years. *Journal of Clinical Oncology*. Jan 1 2002;20(1):282-288.
101. De Bruin ML, Dorresteijn LD, van't Veer MB, et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. *Journal of the National Cancer Institute*. Jul 1 2009;101(13):928-937.
 102. Campen CJ, Kranick SM, Kasner SE, et al. Cranial irradiation increases risk of stroke in pediatric brain tumor survivors. *Stroke*. Nov 2012;43(11):3035-3040.
 103. Xu J, Cao Y. Radiation-induced carotid artery stenosis: a comprehensive review of the literature. *Interventional Neurology*. Aug2014;2(4):183-192.
 104. Gujral DM, Shah BN, Chahal NS, et al. Clinical features of radiation-induced carotid atherosclerosis. *Clin Oncol (R Coll Radiol)*. 2014 Feb;26(2):94-102.
 105. Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. *Cancer*. May 15 2014;120(10):1453-1461.
 106. Epstein JB, Thariat J, Bensadoun RJ, et al. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. *CA Cancer J Clin*. 2012 Nov-Dec;62(6):400-22.
 107. Pinna R, Campus G, Cumbo E, et al. Xerostomia induced by radiotherapy: an overview of the physiopathology, clinical evidence, and management of the oral damage. *Ther Clin Risk Manag*. 2015 Feb 4;11:171-88.
 108. Liu CC, Xia R, Guadagnolo A, et al. Risk of xerostomia in association with the receipt of radiation therapy in older patients with head and neck cancer. *American Journal of Therapeutics*. May 2011;18(3):206-215.
 109. Bar-Ad V, Ohri N, Werner-Wasik M. Esophagitis, treatment-related toxicity in non-small cell lung cancer. *Rev Recent Clin Trials*. 2012 Feb;7(1):31-5.
 110. Baker S, Fairchild A. Radiation-induced esophagitis in lung cancer. *Lung Cancer*. 2016;7:119-127.
 111. Taunk NK, Haffty BG, Kostis JB, Goyal S. Radiation-induced heart disease: pathologic abnormalities and putative mechanisms. *Frontiers in Oncology*. 2015;5:39.
 112. Daniels LA, Krol SD, de Graaf MA, et al. Impact of cardiovascular counseling and screening in Hodgkin lymphoma survivors. *Int J Radiat Oncol Biol Phys*. 2014 Sep 1;90(1):164-71.

113. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. *N Engl J Med*. 2013 Mar 14;368(11):987-98.
114. Wang K, Eblan MJ, Deal AM, et al. Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90Gy. *J Clin Oncol*. May 01 2017;35(13):1387-1394.
115. Mukherjee S, Aston D, Minett M, et al. The significance of cardiac doses received during chemoradiation of oesophageal and gastro-oesophageal junctional cancers. *Clinical Oncology*. May 2003;15(3):115-120.
116. Giridhar P, Mallick S, Rath GK, Julka PK. Radiation induced lung injury: prediction, assessment and management. *Asian Pac J Cancer Prev*. 2015;16(7):2613-7.
117. Stacey R, Green JT. Radiation-induced small bowel disease: latest developments and clinical guidance. *Ther Adv Chronic Dis*. 2014 Jan;5(1):15-29.
118. Cheng JC, Wu JK, Huang CM, et al. Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication. *Int J Radiat Oncol Biol Phys*. 2002 Sep 1;54(1):156-62.
119. Ursino S, Greco C, Cartei F, et al. Radiotherapy and hepatocellular carcinoma: update and review of the literature. *European Review for Medical and Pharmacological Sciences*. Oct2012;16(11):1599-1604.
120. Cheng JC, Wu JK, Huang CM, et al. Radiation-induced liver disease after radiotherapy for hepatocellular carcinoma: clinical manifestation and dosimetric description. *Radiother Oncol*. Apr 2002;63(1):41-45.
121. Cohen EP, Robbins ME. Radiation nephropathy. *Seminars in Nephrology*. Sep 2003;23(5):486-499.
122. Rustagi T, Mashimo H. Endoscopic management of chronic radiation proctitis. *World J Gastroenterol*. 2011 Nov 7;17(41):4554-62.
123. Bansal N, Soni A, Kaur P, Chauhan AK, Kaushal V. Exploring the Management of Radiation Proctitis in Current Clinical Practice. *J Clin Diagn Res*. 2016 Jun;10(6):XE01-XE06.
124. Lenz L, Rohr R, Nakao F, et al. Chronic radiation proctopathy: A practical review of endoscopic treatment. *World J Gastrointest Surg*. Feb 27 2016;8(2):151-160.
125. Incrocci L, Slob AK, Levendag PC. Sexual (dys)function after radio-

- therapy for prostate cancer: a review. *Int J Radiat Oncol Biol Phys.* 2002 Mar 1;52(3):681-93.
126. Noronha AF, Mello de Figueiredo E, Rossi de Figueiredo Franco TM, et al. Treatments for invasive carcinoma of the cervix: what are their impacts on the pelvic floor functions? *Int Braz J Urol.* 2013 Jan-Feb;39(1):46-54.
127. Rigaud J, Hetet JF, Bouchot O. [Management of radiation cystitis]. *Prog Urol.* Sep 2004;14(4):568-572.
128. Chan RJ, Webster J, Chung B, et al. Prevention and treatment of acute radiation-induced skin reactions: a systematic review and meta-analysis of randomized controlled trials. *BMC cancer.* 2014;14:53.
129. Bray FN, Simmons BJ, Wolfson AH, Nouri K. Acute and Chronic Cutaneous Reactions to Ionizing Radiation Therapy. *Dermatology and Therapy.* Jun 2016;6(2):185-206.
130. Cormier JN, Askew RL, Mungovan KS, et al. Lymphedema beyond breast cancer: a systematic review and meta-analysis of cancer-related secondary lymphedema. *Cancer.* Nov 15 2010;116(22):5138-5149.
131. Rebegea L, Firescu D, Dumitru M, Anghel R. The incidence and risk factors for occurrence of arm lymphedema after treatment of breast cancer. *Chirurgia.* Jan-Feb2015;110(1):33-37.
132. Ridner SH, Dietrich MS, Stewart BR, Armer JM. Body mass index and breast cancer treatment-related lymphedema. *Support Care Cancer.* 2011 Jun;19(6):853-7.
133. Jereczek-Fossa BA, Marsiglia HR, Orecchia R. Radiotherapy-related fatigue. *Crit Rev Oncol Hematol.* 2002 Mar;41(3):317-25.
134. Maranzano E, De Angelis V, Pergolizzi S, et al. A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres. *Radiother Oncol.* Jan 2010;94(1):36-41.
135. Ng J, Shuryak I. Minimizing second cancer risk following radiotherapy: current perspectives. *Cancer Manag Res.* 2014 Dec 17;7:1-11.
136. Travis LB, Demark Wahnefried W, Allan JM, et al. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. *Nature reviews. Clinical Oncology.* May2013;10(5):289-301.
137. Oeffinger KC, Baxi SS, Novetsky Friedman D, Moskowitz CS. Solid tumor second primary neoplasms: who is at risk, what can we do? *Seminars in Oncology.* Dec 2013;40(6):676-689.
138. Hall EJ, Wu CS. Radiation-induced second cancers: the impact of

- 3D-CRT and IMRT. *Int J Radiat Oncol Biol Phys.* 2003 May 1;56(1):83-8.
139. Wakeford R. The cancer epidemiology of radiation. *Oncogene.* Aug 23 2004;23(38):6404-6428.
140. van Eggermond AM, Schaapveld M, Lugtenburg PJ, et al. Risk of multiple primary malignancies following treatment of Hodgkin lymphoma. *Blood.* 2014 Jul 17;124(3):319-27; quiz 466.
141. Schaapveld M, Aleman BM, van Eggermond AM, et al. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. *The New England Journal of Medicine.* Dec 24 2015;373(26):2499-2511.
142. LeMieux MH, Solanki AA, Mahmood U, et al. Risk of second malignancies in patients with early-stage classical Hodgkin's lymphoma treated in a modern era. *Cancer Med.* 2015 Apr;4(4):513-8.
143. Moss RW. *Questioning Chemotherapy.* Equinox Press, New York. 2000.
144. Riccardi A, Mora O, Tinelli C, et al. Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. *British Journal of Cancer.* 2000, 82, 1254-1260.
145. Abel U. Chemotherapy of advanced epithelial cancer – a critical review. *Biomed Pharmacother.* 1992, 46(10), 439-452.
146. Ettinger DS, Finkelstein DM, Abeloff MD, et al. Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: an Eastern Cooperative Oncology Group randomized study. *J Natl Cancer Inst.* 1992, 84(14), 1077-1084.
147. Chute JP, Chen T, Feigal E, et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. *J Clin Oncol.* 1999, 17(6), 1794-1801.
148. Huisman C, Smit EF, Giaccone G, Postmus PE. Second-line chemotherapy in relapsing or refractory non-small lung cancer: a review. *J Clin Oncol.* 2000, 18(21), 3722-3730.
149. Billingham LJ, Cullen MH. The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer. *Annals of Oncology.* 2001, 12(12), 1671-1675.
150. Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. *Colorectal Cancer Collaborative Group. BMJ.* 2000, 321(7260), 531-535.
151. Schulman KA, Stadtmauer EA, Reed SD, et al. Economic analysis of conventional-dose chemotherapy compared with high-dose

- chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. *Bone Marrow Transplant*. 2003, 31(3), 205-210.
152. King RJB. *Cancer Biology*. Pearson Education. Prentice Hall. Essex, England. 2000.
153. Moss RW. *Questioning Chemotherapy*. Equinox Press, New York. 2000.
154. Yokomizo A, Ono M, Nanri H, et al. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. *Cancer Res*. 1995, 55(19), 4293-4296.
155. Ferlini C, Scambia G, Marone M, et al. Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines. *Br J Cancer*. 1999, 79(2), 257-263.
156. Pollakis G, Goormaghtigh E, Delmelle M, et al. Adriamycin and derivatives interaction with the mitochondrial membrane: O₂ consumption and free radical formation. *Res Commun Chem Pathol Pharmacol*. 1984, 44(3), 445-459.
157. Mizutani H, Tada-Oikawa S, Hiraku Y, et al. Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. *Life Sci*. 2005, 76(13), 1439-1453.
158. Hudis CA, Seidman AD, Crown JP, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. *J of Clin Oncol*. 1996, 14, 58-65.
159. Gandara DR, Vokes E, Green M, et al. Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. *J Clin Oncol*. 2000, 18, 131-135.
160. Shepherd FA. Chemotherapy for non-small-cell lung cancer: Have we reached a new plareau? *Semin Oncol*. 1999, 26, 3-11.
161. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. *J Clin Oncol*. 2000, 18(10), 2095-2103.
162. Hayes DF, Van Zyl JA, Hacking A, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. *J Clin Oncol*. 1995, 13(10), 2556-2566.
163. Denis LJ, Griffiths K. Endocrine treatment in prostate cancer. *Semin Surg Oncol*. 2000, 18(1), 52-74.
164. Schoenlein PV. Molecular cytogenetics of multiple drug resistance.

- Cytotechnology. 1993, 12(1-3), 63-89.
165. Terzi M. Chromosomal variation and the origin of drug-resistant mutants in mammalian cell lines. *Proc Natl Acad Sci U S A*. 1974, 71(12), 5027-5031.
 166. Koski T, Karhu R, Visakorpi T, et al. Complex chromosomal aberrations in chronic lymphocytic leukemia are associated with cellular drug and irradiation resistance. *Vilpo J Eur J Haematol*. 2000, 65(1), 32-39.
 167. Ziemann C, Burkle A, Kahl GF, Hirsch-Ernst KI. Reactive oxygen species participate in *mdr1b* mRNA and P-glycoprotein overexpression in primary rat hepatocyte cultures. *Carcinogenesis*. 1999, 20(3), 407-414.
 168. Iop A, Manfredi AM, Bonura S. Fatigue in cancer patients receiving chemotherapy: an analysis of published studies. *Ann Oncol*. 2004 May;15(5):712-20.
 169. Carey PJ. Drug-induced myelosuppression: diagnosis and management. *Drug Safety*. 2003;26(10):691-706.
 170. Repetto L; CIPOMO investigators. Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey. *Crit Rev Oncol Hematol*. 2009 Nov;72(2):170-9.
 171. Gayathri BN, Rao KS. Pancytopenia: a clinico hematological study. *J Lab Physicians*. 2011 Jan;3(1):15-20.
 172. Bhatt V, Saleem A. Drug-Induced Neutropenia – Pathophysiology, Clinical Features, and Management. *Annals of Clinical & Laboratory Science*. 2004;34(2):131-137.
 173. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. *Cancer*. Jan 15 2004;100(2):228-237.
 174. Vadhan-Raj S. Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents. *Seminars in hematology*. Jan 2009;46(1 Suppl 2):S26-32.
 175. Grunberg SM, Slusher B, Rugo HS. Emerging treatments in chemotherapy-induced nausea and vomiting. *Clin Adv Hematol Oncol*. 2013 Feb;11(2 Suppl 1):1-18; quiz 2 p following 18.
 176. Marx W, Kiss N, McCarthy AL, et al. Chemotherapy-Induced Nausea and Vomiting: A Narrative Review to Inform Dietetics Practice. *J Acad Nutr Diet*. 2016 May;116(5):819-27.
 177. Davidson W, Teleni L, Muller J, et al. Malnutrition and chemother-

- apy-induced nausea and vomiting: implications for practice. *Oncol Nurs Forum*. 2012;39(4):E340-5.
178. Janelins MC, Tejani MA, Kamen C, et al. Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. *Expert Opin Pharmacother*. 2013 Apr;14(6):757-66.
179. Kolak A, Starosławska E, Kubiowski T, et al. Neuropatia obwodowa wywołana chemioterapią [Chemotherapy induced peripheral neuropathy]. *Pol Merkur Lekarski*. 2013 Nov;35(209):292-6.
180. Argyriou AA, Kyritsis AP, Makatsoris T, Kalofonos HP. Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. *Cancer Manag Res*. 2014;6:135-47.
181. van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. *Cochrane Database Syst Rev*. 2008 Apr 16;(2):CD003917.
182. Molinaro M, Ameri P, Marone G, et al. Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs. *BioMed Research International*. 2015;2015:138148.
183. Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. *Internal Medicine Journal*. Apr 2010;40(4):303-307.
184. Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. *Eur J Cancer*. 2013 Sep;49(13):2900-9.
185. Sterba M, Popelova O, Vavrova A, et al. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. *Antioxid Redox Signal*. Mar 10 2013;18(8):899-929.
186. Ries F, Klastersky J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. *Am J Kidney Dis*. 1986 Nov;8(5):368-79.
187. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of Cisplatin Nephrotoxicity. *Toxins*. 2010;2(11):2490-2518.
188. dos Santos NA, Carvalho Rodrigues MA, Martins NM, dos Santos AC. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. *Archives of Toxicology*. Aug 2012;86(8):1233-1250.
189. Widemann BC, Schwartz S, Jayaprakash N, et al. Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy. *Pharmacotherapy*. 2014

- May;34(5):427-39.
190. Randall J, Ream E. Hair loss with chemotherapy: at a loss over its management? *European Journal of Cancer Care*. Jul 2005;14(3):223-231.
 191. Choi EK, Kim IR, Chang O, et al. Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients. *Psychooncology*. 2014 Mar 24.
 192. Yeager CE, Olsen EA. Treatment of chemotherapy-induced alopecia. *Dermatol Ther*. 2011 Jul-Aug;24(4):432-42
 193. Steinbach S, Hundt W, Schmalfeldt B, et al. Effect of platinum-containing chemotherapy on olfactory, gustatory, and hearing function in ovarian cancer patients. *Arch Gynecol Obstet*. 2012 Aug;286(2):473-80.
 194. Bernhardson BM, Tishelman C, Rutqvist LE. Self-reported taste and smell changes during cancer chemotherapy. *Supportive Care in Cancer*. Mar 2008;16(3):275-283.
 195. Qiao J, Fang H. Hand-foot syndrome related to chemotherapy. *CMAJ*. 2012 Oct 16;184(15):E818.
 196. Bartal A, Matrai Z, Szucs A, Liszky G. A daganatterapia egyik dermatologiai mellékhatása, a kez-lab szindróma fobb kezelesi es megelőzési elvei [Main treatment and preventive measures for hand-foot syndrome, a dermatologic side effect of cancer therapy]. *Magy Onkol*. 2011 Jun;55(2):91-8.
 197. Wilson FP, Berns JS. Onco-nephrology: tumor lysis syndrome. *Clin J Am Soc Nephrol*. 2012 Oct;7(10):1730-9.
 198. Mughal TI, Ejaz AA, Foringer JR, Coiffier B. An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome. *Cancer Treat Rev*. 2010 Apr;36(2):164-76.
 199. Raffa RB. Cancer 'survivor-care': II. Disruption of prefrontal brain activation top-down control of working memory capacity as possible mechanism for chemo-fog/brain (chemotherapy-associated cognitive impairment). *J Clin Pharm Ther*. 2013 Aug;38(4):265-8.
 200. Taillibert S. Is systemic anti-cancer therapy neurotoxic? Does chemo brain exist? And should we rename it? *Adv Exp Med Biol*. 2010;678:86-95.
 201. Kesler S, Janelsins M, Koovakkattu D, et al. Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. *Brain, behavior, and immunity*. Mar

- 2013;30 Suppl:S109-116.
202. Davila M, Bresalier RS. Gastrointestinal complications of oncologic therapy. *Nat Clin Pract Gastroenterol Hepatol*. 2008 Dec;5(12):682-96.
203. Gibson RJ, Keefe DM. Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. *Support Care Cancer*. 2006 Sep;14(9):890-900.
204. Avila JG. Pharmacologic treatment of constipation in cancer patients. *Cancer Control*. 2004 May-Jun;11(3 Suppl):10-8.
205. Campos MI, Campos CN, Aarestrup FM, Aarestrup BJ. Oral mucositis in cancer treatment: Natural history, prevention and treatment. *Mol Clin Oncol*. 2014 May;2(3):337-340.
206. Chaveli-Lopez B, Bagan-Sebastian JV. Treatment of oral mucositis due to chemotherapy. *Journal of Clinical and Experimental Dentistry*. Apr 2016;8(2):e201-209.
207. Moss R., *The cancer industry*, 1996
208. Moss R., *Questioning chemotherapy*, 27, 1995
209. Cairns J., *The treatment of diseases and the war against cancer*, *Scientific American*, 253, 5, 51-59, 1985.
210. *Scientific American*, Nov. 1985
211. Abel U., *Der Spiegel*, Spring-Summer 1991
212. Schmahl D., *Experimental development of anticancer drugs – Problems and objectives, strategies and results*, *Current Cancer Research*, 157-243, Spring 1989
213. Greenberg D.S., *A critical look at cancer coverage*, *Columbia Journalism Review*, January-February 1975
214. Cairns J., *The treatment of diseases and the war against cancer*, *Scientific American*, 253, 5, 51-59, 1985
215. Abel U., *Chemotherapy of advanced epithelial cancer*, Hippokrates Verlag, 1990
216. *A dull weapon: Chemotherapy almost useless in treating advanced organic cancer – Provocative theses at the Hamburg Cancer Congress*, *Der Spiegel*, 174-176, 3.3.90
217. Abel U., *Cytostatic therapy of advanced epithelial tumors: A critique*, Hippokrates Verlag, 1990
218. Moss R., *Questioning chemotherapy*, 1995
219. Chlebowski RT, Lillington L, Nystrom JS, Sayre J. Late mortality and levamisole adjuvant therapy in colorectal cancer. *Br J Cancer*. 1994;69(6):1094-1097.

220. Mackillop WJ, Ward GK, O'Sullivan B. The use of expert surrogates to evaluate clinical trials in non-small cell lung cancer. *Br J Cancer*. 1986;54(4):661-667.
221. Powles TJ, Coombes RC, Smith IE, et al. Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. *Lancet*. 1980 Mar 15;1(8168 Pt 1):580-2.
222. DeVita V.T. Jr., et al [editors], *Cancer: Principles and Practice of Oncology*, 1993
223. Moss R., *Questioning chemotherapy*, 1995
224. *Chemotherapy and radiation: Dangers and side effects*, *Cancer Control Journal*, 5, 3/4-5/6, 125, 1979
225. Reich R., Metcascf T., *The facts about chemotherapy*, 175, 1991
226. Moss R., *Questioning chemotherapy*, 1995
227. Bailar J., Smith E., *Progress against cancer?*, *New England Journal of Medicine*. 1986. 314, 1226-1233.
228. *Cancer patient survival: What progress has been made?*, *US General Accounting Office*, 1987
229. Cairns J., *The treatment of disease and the war against cancer*, *Scientific American*, 253, 5, 51-59, 1985
230. Braverman A., *Medical Oncology in the 1990's*, *Lancet*. 1991, 337, 901-902.
231. Moss R., *Questioning chemotherapy*, 1995
232. Jensen JH, Korsgaard P. [We would drop chemotherapy and enjoy life]. *Ekstra Bladet*. 16 Μαρτίου 2012
233. Dreier J. [Chemotherapy or not?]. *Danish Cancer Society*. 19 Μαρτίου 2012
234. Slevin ML, Stubbs L, Plant HJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. *BMJ*. 1990, 300:1458-60.
235. Gotzsche P. *Deadly Medicines and Organized Crime. How Big Pharma Has Corrupted Healthcare*, 2013.
236. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. *Annu Rev Immunol*. 2007;25:267-296.
237. Agarwal S, Busse PJ. Innate and adaptive immunosenescence. *Ann Allergy Asthma Immunol*. Mar 2010;104(3):183-190; quiz 190-182, 210.
238. Chaplin DD. Overview of the immune response. *J Allergy Clin Immunol*. 2010 Feb;125(2 Suppl 2):S3-23.

239. Pio R, Corrales L, Lambris JD. The role of complement in tumor growth. *Adv Exp Med Biol.* 2014;772:229-62.
240. Janeway CA, Travers P, Walport, et al. Principles of innate and adaptive immunity. In: *Immunobiology: The Immune System in Health and Disease*, 5th ed. New York: Garland Sciences; 2001b. <https://www.ncbi.nlm.nih.gov/books/NBK27090/>.
241. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. *Oncogene.* Oct 06 2008;27(45):5932-5943.
242. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. *Science.* Mar 25 2011;331(6024):1565-1570.
243. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. *Immunology.* May 2007;121(1):1-14.
244. Menon S, Shin S, Dy G. Advances in Cancer Immunotherapy in Solid Tumors. *Cancers.* Nov 24 2016;8(12).
245. Papaioannou NE, Beniata OV, Vitsos P, et al. Harnessing the immune system to improve cancer therapy. *Ann Transl Med.* 2016 Jul;4(14):261.
246. Steplewski Z, Thurin M, Kieber-Emmons T. Antibodies: At The Nexus of Antigens and Cancer Vaccines. *J Infect Dis.* Jul 15 2015;212 Suppl 1:S59-66.
247. Saxena A, Wu D. Advances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-life. *Front Immunol.* 2016;7:580.
248. Chen Q, Cheng M, Wang Z, Zhao S. The efficacy and safety of panitumumab plus irinotecan-based chemotherapy in the treatment of metastatic colorectal cancer: A meta-analysis. *Medicine.* Dec 2016;95(50):e5284.
249. Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. *The Lancet. Oncology.* Jun 2016;17(6):e254-262.
250. Wang W, Erbe AK, Hank JA, et al. NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy. *Front Immunol.* 2015;6:368.
251. Seidel UJ, Schlegel P, Lang P. Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. *Front Immunol.* 2013;4:76.
252. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer.* 2012;12(4):252-264.
253. Letendre P, Monga V, Milhem M, Zakharia Y. Ipilimumab: from pre-

- clinical development to future clinical perspectives in melanoma. *Future Oncology*. Mar 2017;13(7):625-636.
254. Menon S, Shin S, Dy G. Advances in Cancer Immunotherapy in Solid Tumors. *Cancers*. Nov 24 2016;8(12).
255. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med*. Aug 19 2010;363(8):711-723.
256. Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. *Journal of Clinical Oncology*. Feb 10 2013;31(5):616-622.
257. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. *N Engl J Med*. Jun 25 2015;372(26):2521-2532.
258. Lee S, Margolin K. Cytokines in cancer immunotherapy. *Cancers*. Oct 13 2011;3(4):3856-3893.
259. Turner MD, Nedjai B, Hurst T, Pennington DJ. Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. *Biochim Biophys Acta*. 2014 Nov;1843(11):2563-2582.
260. Rafique I, Kirkwood JM, Tarhini AA. Immune checkpoint blockade and interferon-alpha in melanoma. *Seminars in Oncology*. Jun 2015;42(3):436-447.
261. Floros T, Tarhini AA. Anticancer Cytokines: Biology and Clinical Effects of Interferon-alpha2, Interleukin (IL)-2, IL-15, IL-21, and IL-12. *Seminars in Oncology*. Aug 2015;42(4):539-548.
262. Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. *Oncoimmunology*. Jun 2016;5(6):e1163462.
263. Wu J, Lanier LL. Natural killer cells and cancer. *Adv Cancer Res*. 2003;90:127-156.
264. Ott PA, Hodi FS, Kaufman HL, et al. Combination immunotherapy: a road map. *J Immunother Cancer*. 2017 Feb 21;5:16.
265. Sayour EJ, Mitchell DA. Manipulation of Innate and Adaptive Immunity through Cancer Vaccines. *J Immunol Res*. 2017;2017:3145742.
266. Thomas S, Prendergast GC. Cancer Vaccines: A Brief Overview. *Methods Mol Biol*. 2016;1403:755-61.
267. Srivatsan S, Patel JM, Bozeman EN, et al. Allogeneic tumor cell vaccines: the promise and limitations in clinical trials. *Hum Vaccin Immunother*. 2014;10(1):52-63.
268. Guo C, Manjili MH, Subject JR, et al. Therapeutic cancer vaccines:

- past, present, and future. *Adv Cancer Res.* 2013;119:421-475.
269. Mohammed S, Bakshi N, Chaudri N, et al. Cancer Vaccines: Past, Present, and Future. *Adv Anat Pathol.* 2016 May;23(3):180-91.
270. Fiedler K, Lazzaro S, Lutz J, Rauch S, Heidenreich R. mRNA Cancer Vaccines. *Recent Results Cancer Res.* 2016;209:61-85.
271. Diken M, Kranz LM, Kreiter S, Sahin U. mRNA: A Versatile Molecule for Cancer Vaccines. *Curr Issues Mol Biol.* 2017;22:113-128.
272. Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: A new era of cancer treatment at dawn. *Cancer Science.* Oct 2016;107(10):1373-1379.
273. Lawler SE, Speranza MC, Cho CF, Chiocca EA. Oncolytic Viruses in Cancer Treatment: A Review. *JAMA Oncol.* Jul 21 2016.
274. Bartlett DL, Liu Z, Sathaiyah M, et al. Oncolytic viruses as therapeutic cancer vaccines. *Molecular Cancer.* Sep 11 2013;12(1):103.
275. Banday AH, Jeelani S, Hrubby VJ. Cancer vaccine adjuvants – recent clinical progress and future perspectives. *Immunopharmacol Immunotoxicol.* 2015 Feb;37(1):1-11.
276. Liang W, Wang H, Sun TM, et al. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. *World J Gastroenterol.* 2003 Mar;9(3):495-8.
277. Moss R., Questioning chemotherapy, 1995
278. Bailar J., Smith E., Progress against cancer?, *New England Journal of Medicine.* 1986. 314:1226-1232.
279. Ingram B., *Medical Tribune,* 33, 4, 1, Feb., 1992
280. Bailar JC, Smith EM, Progress against Cancer? *N Engl J Med* 1986; 314:1226-1232.
281. Bailar JC, Gornik HL. Cancer Undefeated. *N Engl J Med* 1997; 336:1569-1574.
282. Weiss R., *Science News,* 165, Sept. 12, 1987.
283. Abel U., Chemotherapy of advanced epithelial cancer: A Critical Survey, Hippokrates Verlag Stuttgart, 1990
284. Kaldor JM, Day NE, Pettersson F, et al. Leukemia following chemotherapy for ovarian cancer. *N Engl J Med* 1990; 322:1-6.
285. Nakagawa T, Yasuno M, Tanahashi H, et al. A case of acute myocardial infarction: Intracoronary thrombosis in two major coronary arteries due to hormone therapy. *Angiology,* 1994, 45, 5.
286. Pavlidis NA, Petris C, Briassoulis E, et al. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. *Cancer.* 1992 Jun 15;69(12):2961-4.
287. Catherino WH, Jordan VC. A risk-benefit assessment of tamoxifen

- therapy. *Drug Saf.* 1993 May;8(5):381-97.
288. Seoud MA, Johnson J, Weed JC Jr. Gynecologic tumors in tamoxifen-treated women with breast cancer. *Obstet Gynecol.* 1993 Aug;82(2):165-9.
289. Johansson JE, Adami HO, Andersson SO, et al. High 10-year survival rate in patients with early, untreated prostatic cancer. *JAMA.* 1992 Apr 22-29;267(16):2191-6.
290. Temple NJ, Burkitt DP. The war on cancer – failure of therapy and research: discussion paper. *J R Soc Med.* 1991;84(2):95-98.
291. Lynes B., *The Healing of cancer*, 52, 1989.
292. Walters R., *Options – The alternative cancer therapy book*, 1993.
293. Ράιχ Β., *Ο Συσσωρευτής Οργάνης. Η ιατρική και επιστημονική του χρήση*, εκδ. Χρίστου Μουσουλιώτη
294. Chowka P.B., *The National Cancer Institute and the fifty year cover up*, *East West Journal*, Jan. 1978.
295. Atkins R., *Dr. Atkins health revolution: How complementary medicine can extend your life*, 324-325, 1990.
296. Coleman V., *How To Stop Your Doctor Killing You*. 2019.
297. Hot S.T., *Cancer? Think curable. The Gerson therapy*, 1983
298. Gonzalez NJ. *One man alone: An investigation of nutrition, cancer and William Donald Kelley*, 1987
299. Walters R., *Options – The alternative cancer therapy book*, 1993
300. Samid D., Sherman L.T., Rimoldi D., Induction of phenotypic reversion and terminal differentiation in tumor cells by antineoplaston AS2-1, περίληψη, Ένατο Διεθνές Συνέδριο Μελλοντικών Τάσεων στη Χημειοθεραπεία, Γενεύη, 26-28 Μαρτίου 1990.
301. Muldoon T.G., Copland J.A., Lehner A.F., Hendry L.B., Inhibition of spontaneous mouse mammary tumour development by antineoplaston A10. 1987. *Drugs Under Experimental and Clinical Research*, 13.
302. Moss R., *The cancer industry*, 1989.
303. Brown A.J., *Dr. Lawrence Burton – Cancer researcher in exile*, *Cancer Victory Bulletin*, 7, 2, Feb. 1981
304. Tropp J., *Cancer, a healing crisis*, 1980
305. Lynes B., *The healing of cancer*, 1990
306. Walters R., *Options – The alternative cancer therapy book*, 1993

ΜΕΡΟΣ VII

1. Beard J. Trypsin and amylotrypsin in cancer. *Medical Record*. June 23, 1906, 1020.
2. Sarue M, Standop S, Standop J, et al. Pancreatic enzyme extract improves survival in murine pancreatic cancer. *Pancreas*. 2004, 28(4), 401-12.
3. Gonzalez NJ, Isaacs LL. Evaluation of pancreatic proteolytic enzyme treatment of adenocarcinoma of the pancreas, with nutrition and detoxification support. *Nutr Cancer*. 1999, 33(2), 117-124.
4. Moss RW. Enzymes, trophoblasts, and cancer: the afterlife of an idea (1924-2008). *Integr Cancer Ther*. 2008;7(4):262-275.
5. Beuth J, Ost B, Pakdaman A, et al. Impact of complementary oral enzyme application on the postoperative treatment results of breast cancer patients—results of an epidemiological multicentre retrospective cohort study. *Cancer Chemother Pharmacol*. 2001;47(suppl 1):S45-S54.
6. Edakkanambeth Varayil J, Bauer BA, Hurt RT. Over-the-counter enzyme supplements: what a clinician needs to know. *Mayo Clin Proc*. 2014;89(9):1307-1312.
7. Gujral MS, Patnaik PM, Kaul R, et al. Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers. *Cancer Chemother Pharmacol*. 2001;47(suppl):S23-S28.
8. Kaul R, Mishra BK, Sutradar P, et al. The role of Wobe-Mugos in reducing acute sequelae of radiation in head and neck cancers—a clinical phase-III randomized trial. *Indian J Cancer*. 1999;36(2-4):141-148.
9. Dale PS, Tamhankar CP, George D, Daftary GV. Co-medication with hydrolytic enzymes in radiation therapy of uterine cervix: evidence of the reduction of acute side effects. *Cancer Chemother Pharmacol*. 2001;47(suppl):S29-S34.
10. Paradis ME, Couture P, Gignoux I, et al. Impact of systemic enzyme supplementation on low-grade inflammation in humans. *Pharma-Nutrition*. 2015;3(3):83-88.
11. Kong F, Gao F, Chen J, et al. Elevated serum C-reactive protein level predicts a poor prognosis for recurrent gastric cancer. *Oncotarget*. 2016;7(34):55765-55770.
12. Asegaonkar SB, Asegaonkar BN, Takalkar UV, et al. C-Reactive pro-

- tein and breast cancer: new insights from old molecule. *Int J Breast Cancer*. 2015;2015:145647.
13. Janik S, Bekos C, Hacker P, et al. Elevated CRP levels predict poor outcome and tumor recurrence in patients with thymic epithelial tumors: a pro- and retrospective analysis. *Oncotarget*. 2017;8(29):47090-47102.
 14. Shrotriya S, Walsh D, Bennani-Baiti N, et al. C-Reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: a systematic review. *PLoS One*. 2015;10(12):e0143080.
 15. Sakalova A, Bock PR, Dedik L, et al. Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma. *Cancer Chemother Pharmacol*. 2001;47(suppl):S38-S44.
 16. Beuth J. Proteolytic enzyme therapy in evidence-based complementary oncology: fact or fiction? *Integr Cancer Ther*. 2008;7(4):311-316.
 17. Lane WI, Comae L. *Sharks Don't Get Cancer: How Shark Cartilage Could Save Your Life*. Avery, New York. 1992.
 18. Lane WI, Comae L. *Sharks Still Don't Get Cancer*. Avery, New York. 1996.
 19. Gonzalez RP, Soares FS, Farias RF, et al. Demonstration of inhibitory effect of oral shark cartilage on basic fibroblast growth factor-induced angiogenesis in the rabbit cornea. *Biol Pharm Bull*. 2001, 24(2), 151-154.
 20. Brem H, Folkman J. Inhibition of tumor angiogenesis mediated by cartilage. *J Exp Med*. 1975, 141(2), 427-439.
 21. Random Samples. Sharks do get cancer. *Science*. 2000, 288(5464), 259.
 22. Lee A, Langer R. Shark cartilage contains inhibitors of tumor angiogenesis. *Science*. 1983. 221(4616), 1185-1187.
 23. Langer R, Brem H, Falterman K, et al. Isolations of a cartilage factor that inhibits tumor neovascularization. *Science*. 1976, 193(4247), 70-72.
 24. Moses MA, Sudhalter J, Langer R. Identification of an inhibitor of neovascularization from cartilage. *Science*. 1990, 248(4961), 1408-1410.
 25. Liu N, Lapcevich RK, Underhill CB, et al. Metastatin: a hyaluronan-binding complex from cartilage that inhibits tumor growth.

- Cancer Res. 2001, 61(3), 1022-1028.
26. Prudden JF. The treatment of human cancer with agents prepared from bovine cartilage. *J Biol Response Mod.* 1985, 4(6), 551-584.
 27. Horsman MR, Alsner J, Overgaard J. The effect of shark cartilage extracts on the growth and metastatic spread of the SCCVII carcinoma. *Acta Oncologica.* 1998, 37(5), 441-445.
 28. Barber R, Delahunt B, Grebe SK, et al. Oral shark cartilage does not abolish carcinogenesis but delays tumor progression in a murine model. *Anticancer Res.* 2001, 21(2A), 1065-1069.
 29. Miller DR, Anderson GT, Stark JJ, et al. Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. *J Clin Oncol.* 1998, 16(11), 3649-3655.
 30. Batist G, Patenaude F, Champagne P, et al. Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. *Ann Oncol.* 2002, 13(8), 1259-1263.
 31. Loprinzi CL, Levitt R, Barton DL, et al. Evaluation of shark cartilage in patients with advanced cancer. *Cancer.* 2005 Jul 1;104(1):176-82.
 32. Sheu JR, Fu CC, Tsai ML, Chung W. Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities. *J Anticancer Res.* 1998, 18(6A), 4435-4441.
 33. Gingras D, Renaud A, Mousseau N, Beliveau R. Shark cartilage extracts as antiangiogenic agents: smart drinks or bitter pills? *Cancer Metastasis Rev.* 2000, 19(1-2), 83-86.
 34. Berbari P, Thibodeau A, Germain L, et al. Antiangiogenic effects of the oral administration of liquid cartilage extract in humans. *J Surg Res.* 1999, 87(1), 108-113.
 35. Chao J, Kim Y. Sharks: a potential source of antiangiogenic factors and tumor treatments. *Mar Biotechnol (NY).* 2002, 4(6), 521-525.
 36. Hassan ZM, Feyzi R, Sheikhan A, et al. Low molecular weight fraction of shark cartilage can modulate immune responses and abolish angiogenesis. *Int Immunopharmacol.* 2005, 5(6), 961-970.
 37. Kwon HY, Hong SP, Hahn DH, Kim JH. Apoptosis induction of Persicace Semen extract in human promyelocytic leukemia (HL-60) cells. *Arch Pharm Res.* 2003, 26(2), 157-161.
 38. Ovejera AA, Houchens DP, Barker AD, Venditti JM. Inactivity of DL-amygdalin against human breast and colon tumor xenografts in athymic (nude) mice. *Cancer Treat Rep.* 1978. 62(4), 576-578.
 39. Fukuda T, Ito H, Mukainaka T, et al. Anti-tumor promoting effect of glycosides from *Prunus persica* seeds. *Biol Pharm Bull.* 2003, 26(2),

- 271-273.
40. Chitnis MP, Adwankar MK, Amonkar AJ. Studies on high-dose chemotherapy of amygdalin in murine P388 lymphocytic leukaemia and P815 mast cell leukaemia. *J Cancer Res Clin Oncol*. 1985. 109(3), 208-209.
 41. Koeffler HP, Lowe L, Golde DW. Amygdalin (Laetrile): effect on clonogenic cells from human myeloid leukemia cell lines and normal human marrow. *Cancer Treat Rep*. 1980, 64(1), 105-109.
 42. Wodinsky I, Swiniarski JK. Antitumor activity of amygdalin MF (NSC-15780) as a single agent and with beta-glucosidase (NSC-128056) on a spectrum of transplantable rodent tumors. *Cancer Chemother Rep*. 1975. 59(5), 939-950.
 43. Laster WR, Schabel FM. Experimental studies of the antitumor activity of amygdalin MF (NSC-15780) alone and in combination with beta-glucosidase (NSC-128056). *Cancer Chemother Rep*. 1975, 59(5), 951-965.
 44. Hill GJ, Shine TE, Hill HZ, Miller C. Failure of amygdalin to arrest B16 melanoma and BW5147 AKR leukaemia. *Cancer Res*. 1976, 36(6), 2102-2107.
 45. Stock CC, Martin DS, Sugiura K, et al. Antitumor tests of amygdalin in spontaneous animal tumor systems. *J Surg Oncol*. 1978, 10(2), 89-123.
 46. Ellison NM, Byar DP, Newell GR. Special report on Laetrile: the NCI Laetrile Review. Results of the National Cancer Institute's retrospective Laetrile analysis. *N Engl J Med*. 1978, 299(10), 549-552.
 47. Moertel CG, Fleming TR, Rubin J, et al. A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. *N Engl J Med*. 1982, 306(4), 201-206.
 48. Schmidt ES, Newton GW, Sanders SM, et al. Laetrile toxicity studies in dogs. *JAMA*. 1978, 239(10), 943-947.
 49. Sadoff L, Fuchs K, Hollander J. Rapid death associated with laetrile ingestion. *JAMA*. 1978, 239(15), 1532.
 50. Beamer WC, Shealy RM, Prough DS. Acute cyanide poisoning from laetrile ingestion. *Ann Emerg Med*. 1983. 12(7), 449-451.
 51. Braiko KT, Humbert JR, Terplan KL, Lehotay JM. Laetrile intoxication. Report of a fatal case. *N Engl J Med*. 1979, 300(5), 238-240.
 52. Hall AH, Linden CH, Kulig KW, Rumack BH. Cyanide poisoning from laetrile ingestion: role of nitrite therapy. *Pediatrics*. 1986, 78(2), 269-272.

53. Moertel CG, Ames MM, Kovach JS, et al. A pharmacologic and toxicological study of amygdalin. *JAMA*. 1981, 245(6), 591-594.
54. Holzbecher MD, Moss MA, Ellenberger HA. The cyanide content of laetrile preparations, apricot, peach and apple seeds. *J Toxicol Clin Toxicol*. 1984, 22(4), 341-347.
55. Carter JH, MeLafferty MA, Goldman P. Role of the gastrointestinal microflora in amygdalin (laetrile)-induced cyanide toxicity. *Biochem Pharmacol*. 1980, 29(3), 301-304.
56. Ames MM, Moyer TP, Kovach JS, et al. Pharmacology of amygdalin (laetrile) in cancer patients. *Cancer Chemother Pharmacol*. 1981, 6(1), 51-57.
57. Ames MM, Kovach JS, Flora KP. Initial pharmacologic studies of amygdalin (laetrile) in man. *Res Commun Chem Pathol Pharmacol*. 1978, 22(1), 175-185.
58. Willhite CC. Congenital malformations induced by laetrile. *Science*. 1982, 215(4539), 1513-1515.
59. Janssen WF. Cancer quackery – the past in the present. *Semin Oncol*. 1979, 6(4), 526-536.
60. Lerner IJ. The whys of cancer quackery. *Cancer*. 1984, 53(3Suppl), 815-819.
61. Lerner IJ. Cancer quackery. *Psychiatr Med*. 1987, 5(4), 419-429.
62. Syrigos KN, Rowlinson-Busza G, Epenetos AA. In vitro cytotoxicity following specific activation of amygdalin by beta-glucosidase conjugated to a bladder cancer-associated monoclonal antibody. *Int J Cancer*. 1998, 78(6), 712-719.
63. Leitzmann MF, Willet WC, Rimm EB, et al. A prospective study of coffee consumption and the risk of symptomatic gallstone disease in men. *JAMA*. 1999, 281(22), 2106-2112.
64. Stollerman GH, Bisno AL. (eds). Coffee for gallstones. *Hospital Practice*. August 15, 1999, 128.
65. Hildenbrand GL, Hildenbrand LC, Bradford K, Cavin SW. Five-year survival rates of melanoma patients treated by diet therapy after the manner of Gerson: a retrospective review. *Altern Ther Health Med*. 1995, 1, 29-37.



ΜΑΡΙΟΣ ΔΗΜΟΠΟΥΛΟΣ



ΕΚΔΟΣΕΙΣ ETRA
Τ. 2109811753
www.etra.gr